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VACCINATION STUDY ABSTRACT 
 
Objective—To determine whether it is safe to vaccinate pregnant or postpartum mares with a 
commercial modified-live virus vaccine against equine arteritis v rus (EAV).  
Design—Randomized controlled study. 
Animals—73 mares and their foals. 
Procedures—All mares were vaccinated with a commercial modified-live virus vaccine. Mares 
were vaccinated during mid gestation, during late gestation, 2 or 3 days after parturition, or were 
not vaccinated. Foaling outcomes were recorded and serum, blood, milk, and nasopharyngeal 
samples were collected. 
Results—All mares vaccinated in mid gestation foaled without any problems; 21 of 22 mares had 
antibody titers against EAV at time of foaling. Of the 19 mares vaccinated in late gestation, 3 
aborted; antibody titers against EAV were detected in 13 of 15 mares from which serum was 
obtained at the time of foaling. All postparturient vaccinates were seronegative at foaling; all of 
them seroconverted after vaccination. No adverse effects were detecte  in any of their foals. 
Conclusions and Clinical Relevance—When faced with a substantial risk of natural exposure to 
EAV, it would appear to be safe to vaccinate healthy pregnant mares up to 3 months before 
foaling and during the immediate postpartum period. Vaccinating mares during the last 2 months 
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of gestation was associated with a risk of abortion; this risk must be weighed against the much 
greater risk of widespread abortions in unprotected populations of pregnant mares naturally 






VACCINATION STUDY INTRODUCTION 
 
Equine viral arteritis is an infectious disease of equids caused by EAV. Although most 
primary cases of EVA are subclinical infections and therefore unnoticed by horse owners, some 
outbreaks may be associated with the appearance of influenza-like clinical signs, abortions, and 
interstitial pneumonia in neonatal foals.1,2 The risk of abortion in pregnant mares and the potential 
for persistent infection in stallions have important economic ramifications for the horse breeding 
industry. Equine arteritis virus is an enveloped RNA virus belonging to the family Arteriviridae, 
which also includes another viral disease of major veterinary concern, PRRS.3,4 The EAV and 
PRRS viruses are readily inactivated by common disinfectants and detergents. Equine arteritis 
virus survives for only 2 or  3 days at 37oC, although it may survive for at least 75 days at 4oC.5 
Equine viral arteritis is a disease of worldwide concern, with serologic evidence of 
infection being recorded in North and South America, Europe, Australia, Africa, and Asia.1,6 
However, the seroprevalence of EAV infection varies greatly among countries and among equine 
populations within a country. The 1998 National Animal Health Monitoring System equin  
survey7,8 reported that only 2.0% of unvaccinated horses in the United States were seropositive to 
EAV, in contrast to horses imported into California (mostly European Warmbloods) that had a 
seropositive rate of 18.6%. The seroprevalence of EAV infection varies wid ly among horse 
breeds in the United States, with approximately 80% of Standardbreds and 5.4% of 
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Thoroughbreds being seropositive. Most other breeds are believed to have a seroprevalence of < 
2%.1,9–13 Differences in prevalence among breeds may be associated with differences in 
management practices. The low overall rate of seropositivity in someh rs  breeds has enhanced 
the risk of widespread transmission of the EAV in those breeds during outbreaks of EVA. This 
was exemplified during the extensive outbreak of EVA in Thoroughbreds in Kentucky in 1984 
and in the more recent multistate outbreak in Quarter Horses in the United Stats in 2006 and 
2007. 
Transmission of EAV among horses is principally via the respiratory or venereal 
routes.1,14–18 Outbreaks have frequently resulted from breeding a naïve mare with EAV-infective 
semen; the virus is subsequently disseminated to other naïve horses on the premis s via the 
respiratory route. Naturally infected stallions may become persistent carriers of EAV. 
Establishment and maintenance of the carrier state is a testosterone-d pendent event, with the 
virus localized to the accessory sex glands.18–20 Persistently infected stallions may be short-term 
(< 3 months), intermediate (3 to 7 months), or long-term (7 months to several years) carriers.15,19 
Carrier stallions can play a major role in widespread dissemination of the infection and are the 
primary natural reservoir of the virus.6 
Subsequent to aerosol infection in a horse, EAV spreads to the lungs and bronchial lymph 
nodes, and then enters the circulation to be disseminated throughout the body within 2 days.21 
Following infection, virus can be isolated from the nasopharynx for 2 to 14 days, from the buffy 
coat for 2 to 21 days, and from serum or plasma for 7 to 9 days. An inability to isolate virus from 
serum or plasma after 7 to 9 days is associated with the appearance of antibodies at that time.17 
Equine arteritis virus has not been isolated from an infected horse longer at > 28 days after 
infection, except in the semen of carrier stallions.18,22,23  
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The hallmark histologic finding associated with EAV infection is arteritis, and the 
vascular injury likely results from direct virus-mediated injury to the endothelium and muscularis 
media of affected vessels.24–26 The resulting vasculitis is characterized by marked fibrinoid 
necrosis of small muscular arteries, and the increased vascular permeability leads to hemorrhage 
and edema around these vessels.27,28 
A cornerstone of current EVA prevention and control programs in the United States 
involves the targeted use of an MLV vaccine, which has been commercially av i able since 1985. 
This vaccine was derived from an experimental vaccine against EVA that was developed many 
years earlier by serial passage of the experimentally derived highly pat ogenic Bucyrus strain of 
EAV 131 times in primary horse kidney cells followed by 32 times in primary RK cells (ie, 
HK131-RK32).29 However, the original MLV vaccine was not fully attenuated in that i  induced 
abortion in 2 late-gestation mares when injected directly into the fetus or he amniotic sac. 
Subsequently, a vaccine with a higher passage history (131 times in primary horse kidney cells 
followed by 111 times in primary RK cells [ie, HK131-RK111]) was tested and found to be safe 
when used in pregnant pony mares.30 The current commercially available vaccine is derived from 
the latter of these experimental vaccines; it has a passage history of HK131-RK111-Eq Dermis 
24.31 On the basis of findings in the original experimental vaccine study, the manufacturer 
recommends that pregnant mares should not be vaccinated until after foaling.29 
Despite the manufacturer’s recommendation to refrain from use of the vaccine in 
pregnant mares, there have been reports of its use in pregnant mares without ensuing 
complications. There are also anecdotal reports of a few late-term abortions in mares that had 
been previously vaccinated with the MLV vaccine, but without any evidence directly linking 
vaccination with the abortions.32 The study reported here was conducted in an attempt to establish 
whether vaccinating mares during mid or late gestation with an MLV vaccine against EVA would 






VACCINATION STUDY MATERIALS AND METHODS 
 
Animals—A total of 73 mares were used in the study. Mares were predominantly Thoroug breds 
or American Quarter Horses with a small number of Arabians and 1 Gypsy Cobb mare. Mares 
ranged in age from 5 to 25 years of age, and they were pregnant or had foaled recently. None of 
the mares had a history of gestational or peripartum complications. All of them were confirmed 
negative for serum neutralizing antibodies against EAV at the beginning of the study.  Owner 
consent was obtained for all client-owned animals used in the study. The study was approved by 
and conducted in accordance with the guidelines of the Oklahoma State University Institutional 
Animal Care and Use Committee.  
 
Procedures—All mares were maintained at 1 of 2 breeding premises in central Oklahoma for the
duration of the study. Mares in group 1 (n = 22 mid-gestation mares) were vaccinated, housed, 
and foaled at a commercial breeding premises in Guthrie, Oklahoma. Mares in g oup 2 (n = 19 
late-gestation mares) were vaccinated, housed, and foaled at the commerial br eding premises 
(2) or at the Center for Veterinary Health Sciences Ranch in Stillwater, Oklahoma (17). All of the 
mares in group 3 (n = 28 postparturient mares) were vaccinated, housed, and foaled at the Center 
for Veterinary Health Sciences Ranch. The control group consisted of 4 mares (2 were housed at 
the commercial breeding premises and 2 were housed at the Center for Veterinary Health
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 Sciences Ranch) that were not vaccinated. Neither premises had a prior history of EAV infection 
as determined on the basis of routine serosurveillance testing.  
 
Mares in group 1 were vaccinated between 142 and 83 days before foaling, and mares in group 2 
were vaccinated between 68 and 2 days before foaling. Mares in group 3 were vaccinated within 
3 days after foaling. The mares in group 3 were subdivided into 2 subgroups: 16 mares and their 
foals were turned out to pasture following vaccination (pasture subgroup), and 12 mares were 
housed indoors in individual stalls (4.6 X 7.6 m [15 X 25 feet]) with their foals for 10 days 
following vaccination (which enforced close physical contact [stall subgroup]), after which these 
mares and foals were also turned out to pasture. Details of individual mares including the day of 
vaccination relative to the day of foaling are provided in Table 1. 
 
Vaccination of mares—Mares were vaccinated against EVA by IM administration of a single 
dose of a commercially available MLV vaccine.a  Mares were vaccinated in accordance with the 
manufacturer’s instructions.  
 
Management and collection of samples from mares and foals—Management and sample 
collection were based on pregnancy status at the time of vaccination. 
GROUPS 1 AND 2 (PREPARTUM VACCINATES) 
Following vaccination, each mare was monitored daily to evaluate general health as well as 
pregnancy status. As the anticipated date of parturition approached, mares were moved into a 




Blood samples (5 mL) were collected via jugular venipuncture from each mare at the time of 
parturition (0 hours), 12 hours later, and 30 days after parturition. Blood samples (5 mL) were 
similarly collected from each foal immediately after birth befor  they nursed the dam (if 
possible), 12 hours later, and 30 days after parturition. The precolostral blood sample  were 
obtained from the foals via venipuncture of the umbilical vein or jugular vein; blood samples 
were obtained from the foals at 12 hours and 30 days after parturition via jugul r venipuncture. 
Samples were allowed to clot, and the serum was harvested and stored at –20oC. Milk samples 
(10 mL) were collected from each mare at time 0, 12 hours later, and 30 days after parturition. 
 
GROUP 3 (POSTPARTUM VACCINATES) 
Rectal temperature, pulse rate, and respiratory rate were recorded f r each mare and foal at the 
time of parturition, 12 hours after parturition, 48 hours after parturition, and on days 1, 3, 5, 7, 14, 
and 28 after vaccination. The type of samples collected and the sample collection schedule was 
the same for mare-foal pairs of both the stall and pasture subgroups. Blood samples were 
collected from mares at the time of vaccination and on days 14 and 28 after vaccination for serum 
harvest and use in a VN test to detect development of antibodies against EAV. Blood samples 
were also collected from mares into EDTA-containing tubes for separation of peripheral blood 
mononuclear cells for use in virus isolation; these blood samples were collected on the day of 
parturition and days 1, 3, 5, 7, 14, and 28 after vaccination. Blood samples for serum harvest were 
collected by jugular venipuncture from the foals at the time of vaccination nd on days 14 and 28 
after vaccination for use determining possible exposure to vaccine virus. Nasopharyngeal swab 
specimens were collected from mares on the day of vaccination and days 1, 3, 5, 7, 9, 11, 14, and 
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The control mares were housed and handled similarly to the mares in groups 1 and 2, except that 
they were not vaccinated. Blood samples were collected from the mares and their foals at the 
same times as for the horses of groups 1 and 2.  
 
VN titers—Serum and milk samples were subjected to VN tests to detect antibodies aga n t 
EAV. Serum VN antibody titers were determined in accordance with the method described in 
another study.34 
 
Virus isolation—Virus isolation from buffy coat and nasopharyngeal swab specimens was 
performed in RK-13 cells in according with a recommended protocol.35 Briefly, blood samples 
collected into EDTA anticoagulant were centrifuged at 500 X g for 10 minutes. Plasma and buffy 
coat cells were aspirated and placed in 15-mL conical centrifuge tubes. Buffy coat cells were 
pelleted by centrifugation at 1,500 X g for 10 minutes at 4oC. The plasma was aspirated, and the 
WBC pellet was resuspended in 5 mL of EMEM. The cell suspensions were frozen at –80oC until 
virus isolation was performed. Nasopharyngeal swab specimens in viral transpo t medium were 
vortexed and then filtered through a 0.45-µm syringe filter. Filtrates were frozen at –80oC until 
virus isolation could be performed. Virus isolation from peripheral blood mononuclear cells, 
filtrates of nasopharyngeal swab specimens, and clarified 10% fetal tissue suspensions was 
attempted in both high- and low-passage RK-13 cell lines in accordance with a recommended 
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protocol.35 Briefly, serial 10-fold dilutions (10–1 to 10–3) of each sample were made in 
supplemented EMEM, and 1 mL of each dilution was inoculated into 2 X 25-cm2 flasks 
containing confluent monolayers of RK-13 cells. Flasks were incubated at 37oC for 1 hour and 
then were overlaid with EMEM supplemented with 0.75% carboxymethyl cellulose. Flasks were 
incubated at 37oC and evaluated for the appearance of viral cytopathic effect on days 3 nd 4 after 
inoculation. If there were no detectable cytopathic effects, a second passage was performed on 
day 4. The RK-13 cell monolayers were fixed and stained with a 1% crystal violet solution 
containing 1% formaldehyde on day 5 after inoculation in the case of the first passage in cell 
culture and on day 4 after inoculation in the case of the second passage in cell cultur . Tissue 
culture fluid was harvested and stored at –80oC until used for viral RNA extraction. 
 
Viral RNA extraction and real-time RT-PCR—Viral RNA was directly isolated from samples 
of tissue culture fluid by use of a commercial kit.b Briefly, tissue culture fluid samples were 
placed in microcentrifuge tubes and centrifuged at 13,800 X g for 2 minutes; then 140 µL of 
supernatant was removed and used for nucleic acid extraction in accordance with th  
manufacturer’s instructions. Viral nucleic acid was eluted in 60 µL of nuclease-free water and 
stored at –80oC. 
 
A 1-tube real-time RT-PCR assayc was performed with RT-PCR master mixd in a real-time PCR 
system.e The primers and probes used were identical to those previously described.36,37 Every 
sample was tested in duplicate. Briefly, 25 µL of RT-PCR mixture for each reaction contained 
12.5 µL of 2X master mix without uracil-N-glycosylase, 40X reverse transriptase f and RNase 
inhibitor mix,g 900nM forward and reverse primers (0.45 µL), 250nM probe (0.625 µL), 5.35 µL 
of nuclease-free water, and 5 µL of test sample RNA. Thermocycling conditions were used for 
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the standard mode as per manufacturer’s recommendation (30 minutes at 48oC, 10 minutes at 
95oC, 40 cycles at 95oC for 15 seconds, and 60oC for 1 minute). Each RT-PCR assay included a 
negative control sample without RNA (contained the reaction mix with 5 µL of water [no 
template]) and positive control samples. 
 
Postmortem examination—Gross and histologic examination of any aborted fetuses was 
performed at an animal disease diagnostic laboratory.h Tissues were fixed in neutral-buffered 
10% formalin and embedded in paraffin, and sections were stained with H&E. Specimens of f tal 
membranes and fetal lung, heart, and liver were collected for attempted virus isolation and viral 
nucleic acid extraction and stored at –80oC. Tissues were tested for evidence of infection with 
EHV-1, EHV-4, and Leptospira spp. Fluorescent antibody staining and examination of fetal 
tissues for EHV-1 and EHV-4 was performed on approximately 10-µm-thick tissue sections 
which were stained with caprine origin anti–EHV-1 and anti–EHV-4 polyclonal antiserum 
conjugated to fluorescein isothiocyanatei s described in standard  protocols and procedures. 
Sections were counter-stained with Evans blue dye, which caused cells with positive results to 
stain fluorescent green and cells with negative results to stain brick red. Aerobic bacteriologic 
culture of fetal stomach contents, fetal lungs, or fetal membranes was performed on blood agar, 
MacConkey agar, and phenol-ethyl-alcohol agar.38 Heart blood samples were also obtained from 
each fetus for serologic examination.  
 
Statistical analysis—All statistical analyses were conducted with a commercially avail ble 
statistical program.j Repeated-measures ANOVAk was used to assess the effects of parturition 
group and time. Simple effects of parturition group (control vs group 1 vs group 2) for a given 
time were calculated, and comparisons of the groups were performed with pair-wise t tests.l,m 
12 
 
Titer values were transformed with a logarithmic (base 2) function pri r to calculation of the 
ANOVA. Means and SEs of the raw titer values were reported. Significance was set at values of 







VACCINATION STUDY RESULTS 
 
Foaling outcomes—All 22 mares in group 1 foaled without difficulty or assistance, and each 
mare gave birth to a live foal. Serum IgG testing was performed on samples obtained from 20 
foals at 12 hours after birth; all foals had IgG concentrations > 800 mg/dL. Although IgG 
concentrations were not determined for 2 foals, these foals were healthy at birth and remained 
healthy throughout the 30-day study period. Two foals were healthy at birth and had IgG 
concentrations > 800 mg/dL; however, both foals died before 30 days after birth, and regrettably 
neither was submitted for necropsy. 
 
Three mares in group 2 aborted. One mare aborted 9 days after vaccination, a second mare 
aborted 11 days after vaccination, and a third mare aborted 38 days after vaccination.  The 
remaining 16 mares in group 2 foaled without difficulty or assistance, and all foals, except for 1, 
had a serum IgG concentration > 800 mg/dL in samples obtained at 12 hours after birth. The 1 
foal had a serum IgG concentration < 400 mg/dL at 12 hours after birth and was administered 1 L 
of plasma; this foal thrived throughout the 30-day study period. Two foals were euthanized at 
approximately 2 weeks after birth (one of these foals had evidence of severe abdominal pain, and 
an area of devitalized intestine was found during necropsy; the other foal was weak at birth, 
14 
 
dehydrated, and unable to stand, but no significant findings were detected in this foal during 
necropsy).  
 
All 28 mares in group 3 gave birth to healthy foals without difficulty or assistance. Twenty-five 
of these foals had an IgG concentration > 800 mg/dL in samples obtained 12 hours after birth. 
Each of the 3 other foals required a transfusion of 1 L of plasma to increase th serum IgG 
concentration to > 800 mg/dL. All foals in this group remained healthy throughout the 30-day 
study period. 
 
All mares in the control group gave birth to healthy foals without difficulty or assistance. All 
foals had an IgG concentration > 800 mg/dL in samples obtained at 12 hours after birth.  
 
Clinical findings—The mares and foals in all groups were monitored after parturition. Mares and 
foals were generally bright, alert, and active throughout the 28-day period after v ccination, 
except for the 2 aforementioned foals in group 2 that were euthanized. Mares and foals of group 3 
were closely monitored following vaccination, with frequent assessments of rectal temperature, 
pulse, respiration, and overall demeanor. No significant difference from the reference range was 
detected for mean rectal temperature, pulse rate, or respiratory rate ecorded at birth, 12 hours 
after parturition, 48 hours after parturition, and 1, 3, 5, 7, 14, and 28 days after vaccination. 
 
Results of VN tests—All mares were seronegative for EAV at the beginning of the study. 
Serologic data were available on almost all mares and foals over the study period. All of the 
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mares in group 1, except for 1 mare, were seropositive (titer ≥ 1:4) to EAV at foaling; titers for 
the seropositive mares ranged from 1:16 to ≥ 1:512 (Table 2). That 1 mare was seronegative at 
the time of foaling but seropositive (titer ≥ 1:512) 12 hours later. Samples were obtained at 30-
days after parturition from 18 mares, all of which were still seropositive. The mean VN titer for 
the mares differed significantly between the control group and group 1 as well as b tween the 
control group and group 2 at 0 hours, 12 hours, and 30 days.  
 
All 22 foals in group 1 were seronegative (titer < 1:4) at birth, but all were s opositive 12 hours 
later. All of the foals available for sample collection at 30 days after parturition were still 
seropositive. The mean VN titer for foals differed significantly betwe n the control group and 
group 1 as well as between the control group and group 2 at 12 hours, whereas there was no 
significant difference between the control groups or group 1 and 2 at 0 hours. At 30 days after 
parturition, the mean VN titer for foals of group 1 was significantly different from that of the 
control group, whereas the mean VN titer did not differ significantly between the control group 
and group 2. 
 
Similarly, data for milk samples were available for most mares. All mares in group 1 had 
antibodies against EAV in the colostrum at the time of foaling, with 18 of 22 mares having a titer 
≥ 1:512. Milk samples collected 12 hours after foaling had antibodies against EAV for all of the 
mares, although there was a fourfold or greater decrease in antibody titer in many samples. 
Samples collected at 30 days after parturition did not have antibodies against EAV in 7 of 22 
mares and had titers between 1:4 and 1:32 in 8 of 22 mares; the remaining 7 mares were not
available for collection of milk samples. Mean VN titer in milk was not significantly different 
among all groups at 0 hours and was significantly different among all groups at 12 hours; at 30 
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days, the mean VN titer in milk for group 1 was significantly different from that of the control 
group, whereas the mean VN titer did not differ significantly between the control group and 
group 2. 
 
Fifteen of 19 mares in group 2 were available for collection of milk samples. In those 15 mares, 
13 were seropositive and 2 were seronegative at the time of foaling (Table 3). Fifteen foals from 
which samples were collected at the time of birth were seronegative. However, serum obtained 
before colostral suckling from 3 foals were positive for antibodies against EAV. The 4 control 
mares had negative results for antibodies against EAV in serum and milk sa ples obtained 
throughout the study. 
 
Milk was obtained from 15 mares in group 2 at the time of foaling, with 11 milk samples having 
positive results and 4 samples having negative results for antibodies again t EAV. The milk 
samples with negative results were collected from 4 mares that were vaccinated 2, 4, 4, and 19 
days before foaling, respectively. The milk samples obtained 12 hours after parturition still had 
negative results for 3 of these 4 mares (mares vaccinated on 2, 4, and 4 days before foaling, 
respectively; samples were not obtained from the other mare). All group 2 milk samples collected 
at 30 days after parturition had negative results or had low titers (≤ 1:16), except for 1. 
 
The 28 mares and 27 foals comprising group 3 from which samples were available were negative 
for antibodies against EAV at the time of foaling. All of the mares responded following 
vaccination with detectable VN titers at days 14 and 28 after vaccination. All of the foals, except 
for 2, were seronegative at days 14 and 28 after parturition. Both seropositive foals were in the 
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pasture subgroup. The remainder of the foals in the pasture subgroup and the stall subgroup of 
foals were negative for antibodies at birth and 14 and 28 days after foaling (Table 4). 
 
Virus isolation and PCR results—Results of virus isolation for nasopharyngeal swab specimens 
and buffy coat specimens obtained from the mares in group 3 were determined. Because there 
were a number of samples that were not collected, the data set was not complete for all mares. All 
samples with positive results for virus isolation were confirmed by use of real-time RT-PCR 
assay. 
 
Twelve of 28 mares in group 3 had positive results for virus isolation of buffycoat specimens or 
nasopharyngeal swab specimens. Equine arteritis virus was isolated from the buffy coat of 9 
mares in the period immediately following vaccination, 8 of which were in the pasture subgroup 
(the remaining mare with the positive results was in the stall subgro p). Virus was isolated from 
the nasopharynx of 5 mares, including 2 from the pasture subgroup and 3 from the stallsubgroup. 
Two of the 12 mares with positive results for EAV had virus isolated fromb th the buffy coat 
specimens and nasopharyngeal swab specimens.  Most of the virus isolations were from 
specimens collected within the first few days after vaccination. 
 
Two foals seroconverted to EAV after vaccination of their respective dams; both mares had 
positive results for virus in the buffy coat specimens. However, EAV was not detected in 
nasopharyngeal swab specimens collected from either of these mares. Both of the mares were in 





Postmortem examination—Fetuses aborted by 3 mares in group 2 were submitted for a 
complete postmortem evaluation. The fetus from 1 mare was close to full term (approx 300-330 
days of gestation). Gross examination of that fetus revealed multiple nonspecific lesions, 
including mild, multifocal, hemorrhage in the thymus and heart; mild mesenteric 
lymphadenopathy; and mild, acute, multifocal hemorrhage of the allantoic sac and chorioallantois 
in conjunction with chorioallantoic edema. The fetal membranes weighed 5.1 kg (1 .2 lb). 
Histologically, lesions consistent with arteritis were observed as well as stromal neutrophilic 
infiltration and fibrinous inflammation of the chorioallantois and amniotic sac; arteritis with 
neutrophilic and fibrinous perifunisitis; mild hemorrhages of the kidneys, thymus, and adrenal 
glands; and hyperplasia of the lymphoid follicles of the spleen and mesenteric lymph nodes. The 
lungs were atelectic and not aerated, and meconium was found in the lumen of the alveoli and 
airways. Lung tissue from the foal had positive results for EAV by use of the PCR assay. The 
fetus was seronegative for antibodies against EAV, EHV-1, and Leptospira spp. Fluorescent 
antibody staining of sections of the liver yielded negative results for EHV-1 and EHV-4 antigens. 
Aerobic bacteriologic culture of fetal stomach contents also yielded negativ  results. 
 
Necropsy of the aborted fetus and fetal membranes from a second mare that borted revealed 
heavy (8.5 kg [18.7 lb]), edematous fetal membranes, a nearly full-term fetus, adrenal gland 
hemorrhage, and diffusely atelectic lungs. Histologic examination revealed chronic inflammatory 
lesions around blood vessels in the heart and in the stroma of the thickened areas of th  fetal 
membranes. The fetus and fetal membranes had positive results for EAV by use of PCR assay. 
The fetus was seronegative for EAV, EHV-1, and several serovars of Leptospira interrogans 
(Canicola, Grippotyphosa, Icterohemorrhagica, Pomona, Bratislava, and Hardjo). Fluorescent 
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antibody staining of sections of the lungs and liver yielded negative results for EHV-1 and EHV-
4 antigens. Aerobic bacteriologic culture of fetal stomach contents also yie ded negative results. 
 
Fetal membranes were the only tissue available for evaluation following the abortion of the third 
mare. The fetal membranes were heavy (8.6 kg [18.9 lb]), with marked thickening and edema of 
the entire allantochorion in the region of the pregnant horn and adjacent uteri e body. Histologic 
examination confirmed stromal edema and congestion in the thickened areas of the fetal 
membranes. The fetal membranes had positive results for EAV by use of PCR assay. Aerobic 
bacteriologic culture of the fetal membranes yielded a moderate growth of Klebsiella pneumonia, 
α-Streptococcus pp, Escherichia hermanii, Raltonia picketii, Acinetobacter wolfii, and 
Enterobacter gergoviae; all were considered bacterial contaminants. Fungal culture of the fetal 
membranes yielded a growth of a small number of colonies of Penicillium spp. The fetal 
membranes had negative results for EHV-1 and EHV-4 by use of PCR assay. Leptospiral 
evaluation revealed titers against several L interrogans serovars (Grippotyphosa, 1:1,600; 
Icterohemorrhagica, 1:400; and Bratislava, 1:400); results were negative for several other L









VACCINATION STUDY DISCUSSION 
 
The economic impact of an outbreak of EVA can be substantial, as was the case 
following outbreaks on Thoroughbred breeding farms in Kentucky in 1984 and the multistate 
outbreak in  Quarter Horses in 2006 and 2007. Breeding farms can be especially hit hard 
economically. The question frequently arises as to the best time to vaccinate broodmares against 
EVA to minimize or prevent the risk of widespread abortions. The primary objective of the study 
reported here was to provide an answer to this question. 
To address this objective, mares were vaccinated during pregnancy (mid or late gestation) 
or immediately after parturition, which are often the time points when breeders want to vaccinate 
mares to protect them against the risk of natural infection with EAV. The only commercially 
available vaccine against EVAa in the United States was used; this vaccine is not recommended 
for use in pregnant mares. The vaccine insert indicates that pregnant mares should not be 
vaccinated until after foaling. Furthermore, pregnant mares should not bevaccinated during the 
last 2 months of gestation because a few instances of fetal invasion by vaccine virus have been 
detected after vaccination during this period. It is preferable to vaccinate mares when they are not 
pregnant; however, when pregnant mares are threatened by a high risk of natural exposure, 
vaccination may be undertaken with considerably less risk of abortion atributable to vaccination 
than is inherent for natural infection. Owners should be advised of the possibility of fetal 
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infection before vaccinating pregnant mares. The results of the present study support this 
recommendation. 
The findings of the study reported here are consistent with those in another study39 in 
which investigators found that the vaccine virus was associated with an isol ted abortion in a 
mare recently vaccinated with the commercially available vaccine.a In that study,39 there was 
homology between the nucleotide sequence of open reading frame 5 of the isolated virus and that 
of the vaccine virus. The mare aborted during the midst of an extensive outbrak of EVA on a 
Thoroughbred breeding farm in Illinois in 1994. In contrast to this finding, results of a subsequent 
study31 were reported for the outcome after vaccinating 5 pregnant mares with the commercially 
available vaccinea between 51 and 85 days prior to foaling. Vaccination against EVA with the 
MLV vaccine did not result in abortion in any of the vaccinated mares. As emphasized by the 
authors of that study,31 this finding must be interpreted with caution in light of the small number 
of horses involved. It is worth mentioning that following the 2006 and 2007 multistate outbreak 
of EVA, there was widespread use of the same MLV vaccine in pregnant mares with no 
published reports of confirmed abortions associated with vaccination. 
Studies in which the vaccine strain of EAV was administered to mares include those 
conducted by researchers instrumental in the development of the vaccine in the 1960s and 1970s. 
The original vaccine inoculated directly into a fetus or amniotic sac induced abortion in 2 
mares.29 A subsequent study30 that involved the IM administration of a vaccine virus with a 
higher passage history did not result in any abortions in 18 mares vaccinated at 30 ays of 
gestation to nearly the end of a full-term gestation. The present study i  the largest study 
conducted to assess the effects of vaccination with the MLV vaccine against EVA in peripartum 
mares. Furthermore, the passage history of the vaccine virus was much higher than that of the 
modified-live experimental vaccines used in earlier studies.29,30 
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Of the 22 mares in group 1 (mares vaccinated in mid gestation), all gave birth to l ve 
healthy foals. Twenty foals remained healthy throughout the study. The 2 foals that died before 
30 days after birth appeared to have died of apparently unrelated illness, notwithstanding the fact 
that a postmortem examination was not performed on either foal. Furthermore, there was no 
evidence of congenital EAV infection in that every foal was seronegativ for antibodies against 
EAV at birth. All of the foals were seropositive at 12 hours after birth, which confirmed effective 
absorption of colostral-derived antibodies from their dams. One mare in this group was 
seronegative for EAV at the time of foaling, but both that mare and her foal had a titer ≥ 1:512 12 
hours later, and the milk obtained from that mare at the time of foaling had positive results for 
antibodies (titer, ≥1:512). This discrepant result would strongly suggest that the sample identified 
as that of the mare at 0 hours was probably mislabeled and that it actually represented the sample 
obtained from the foal at 12 hours after birth. It is important that all foalswere seronegative for 
EAV at birth and were subsequently seropositive at 12 hours and 30 days after parturition, which 
indicated that vaccination of mid-gestation mares does not result in exposure of the unborn fetus 
to vaccine virus and that colostrum does provide passive protection against EVA in the case of 
newborn foals.40 The findings indicated that vaccination with the commercially avail ble vaccinea 
between 83 and 142 days before the anticipated date of foaling does not compromise maintenance 
of pregnancy nor result in congenital infection of a the fetus. 
It is important to consider the neutralizing antibody concentration that is suff cient to 
afford protection against wild-type EAV infection. In 1 study,41 titers as low as 1:8 were fully 
protective, and titers of 1:4 were moderately protective, when horses wer challenge exposed to a 
highly virulent Bucyrus strain of EAV. All mares in the study reported h re had fully protective 
titers of 1:8 or higher at 30 days after parturition. 
In contrast to the fact that none of the vaccinated mares in group 1 aborted, 3 of 19 mares 
in group 2 (all mares were vaccinated during late gestation) aborted. Th mares in group 2 
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aborted 9, 11, and 38 days after vaccination, respectively. Tissues from all 3 aborted fetuses had 
positive results for EAV by use of virus isolation and PCR assay. In light of the fact that all foals 
in group 1 were seronegative at birth, it must be assumed that these foals did not have EAV 
infection in utero. In contrast, detection of EAV in tissues of the 3 aborted foals in group 2 was 
important. Considered in conjunction with other findings, it would appear that EAV was a factor 
in causing abortion in each of these 3 mares. Unfortunately, the aborted fetus from 1 mare was 
not recovered (the mare aborted unexpectedly in a pasture, and the fetus was not found). This 
mare also had a high titer to L interrogans serovar Grippotyphosa, with moderate titers also to L 
interrogans serovars Icterohemorrhagica and Bratislava. Because of the lack of any histologic 
confirmation of EAV infection and in light of the titers for leptospiros s, the abortion of that mare 
cannot unequivocally be attributed solely to EAV. 
The mare that aborted while in a pasture and whose fetus was not recovered aborted 38 
days after vaccination, as opposed to the other 2 mares that aborted 9 and 11 days after 
vaccination, respectively. The closer temporal association of the abortions with vaccination in 
those 2 mares in addition to the histologic findings in the aborted fetuses provided a stronger case 
for involvement of the vaccine strain of EAV in each of these abortions. The lesions of arteritis 
observed in the chorioallantois and umbilical cord in association with the positive PCR findings 
and nondetectable or marginal titers for leptospirosis would point to thevaccine strain of EAV as 
the likely cause of the abortion in the mare that aborted 11 days after vaccination. Similar 
findings, including chronic inflammation around the blood vessels in the heart and fet l 
membranes, for the mare that aborted 9 days after vaccination would also support this conclusion. 
The homology of the nucleotide sequence of open reading frames 2a to 7 of the isolated virus and 
the corresponding region of the vaccine virus implicated the vaccine strain of EAV as the cause 
of the abortions. It is worth mentioning that samples of fetal heart blood collected from the 
aborted fetuses of the mares that aborted 9 and 11 days after vaccination, respectively, were 
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negative for antibodies against EAV, which suggested that the immune system of these fetuses 
did not have time to respond to circulating vaccine virus before fetal death occurred. 
Further supportive evidence of the possibility of in utero fetal infection wth the vaccine 
virus was the finding of presuckle serum titers against EAV in a limited number of foals in group 
2. In contrast to group 1, in which all of the foals were born seronegative to EAV, 3 of 18 foals in 
group 2 were born seropositive to EAV. The dams of these 3 foals were vaccinated 13, 36, and 68 
days before foaling. The titers confirmed that in utero fetal infection with EAV had taken place. It 
is worth mentioning that all 3 foals were born healthy and remained healthy throughout the 
duration of the study. Because the fetal membranes from apparently normal births we e not 
routinely collected and subjected to virus isolation, PCR assay, or histologc examination, it is 
unknown whether there may have been evidence of infection by EAV in the fetal membrane 
tissues of these 3 foals. 
The virus isolated from each animal represented the vaccine virus rather than wild-type 
virus acquired during the course of the study. Although neither virus isolation nor PCR assay 
differentiates vaccine virus from wild-type virus, there was no other sou ce of EAV during this 
study, except for the vaccination. Despite vigilant surveillance, EAV was not detected on any 
premises in Oklahoma during the time of the study. Neither the control mares nor other 
nonvaccinated horses on the breeding farms where the study was conducted seroconverted during 
the study. 
The intent of the vaccination protocol used in mares in group 3 was to assessthe 
responses of the mare and foal if the mare was vaccinated with the MLV vaccine within 2 to 3 
days after foaling. All of the mares seroconverted as expected, and all of the f als (except for 2) 
remained seronegative throughout the study. The 2 foals that were seropositive were clinically 
normal on the basis of results of physical examination, and their heart rate, espiratory rate, and 
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rectal temperature were not significantly different from those of their cohorts. It was thought that 
close contact between the mare and foal during the immediate postpartum e iod might increase 
the chance of transmission of the vaccine virus from mare to foal. Surprisingly, the 2 foals with 
positive results for antibodies against EAV were both part of the pasture subset. It could be 
argued that mares and foals housed in pastures likely have similar patterns of physical contact to 
those confined in stalls. Twelve of 28 mares in group 3 that had positive results for EAV during 
virus isolation or PCR assay of either buffy coat specimens or nasopharyngeal swab specimens 
comprised mares from both the pasture subgroup (n = 9 mares) and the stall subgroup (3). 
Apparently, only 2 of the 12 virus-positive mares shed a sufficient amount of virus to infect their 
foals, as attested to by seroconversion of the foals. Neither of these 2 foals had any clinical signs 
of illness. The titers in the foals were the result of exposure to the vaccine virus by some 
undefined route, perhaps via the milk. On the basis of findings in the present study, it does not 
appear to be detrimental to vaccinate mares 2 to 3 days after foaling, although there is a low risk 
that the foal may become infected with the vaccine virus through contact wih i s vaccinated dam. 
It would be prudent to recommend against vaccinating a mare soon after foaling if there was any 
compromise of the foal’s health. If there is a need to vaccinate a mare during the immediate 
postpartum period, blood should be collected from her foal prior to vaccination of the mare to 
document seronegative status, and the foal could then be considered potentially vaccinated on that 
date if detected seropositive to EAV 14 to 28 days after vaccination of the dam. 
It was hypothesized that the 16 of 28 mares in group 3 that were not EAV-positive during
virus isolation or PCR assay of buffy coat specimens or nasopharyngeal swab specimens had 
negative results because of enhanced clearance of vaccine virus associated with the peripartum 
period. The immune system of these mares may have been more aggressive in achi vi g 
pathogen clearance during the peripartum period, as suggested by vaccination studies in 
humans.42,43 It is interesting that the CDC recommendation for vaccination of a pregnant woman 
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seronegative for antibodies against tetanus, diphtheria, and pertussis is to vaccinate during the 
postpartum period with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis 
vaccine.42 Despite the lack of any documented complications associated with prepartum 
vaccination, the CDC believes it prudent to make this recommendation, presumably for the same 
reasons the manufacturer of the commercially available vaccine against EAVa makes the same 
recommendation. In studies44–46 in dairy cows, it has been found that there are dramatic decreases 
in the percentage of peripheral blood CD4+ T cells as well as increased activity of CD8+ 
lymphocytes at parturition. Peripheral blood B-cell concentrations are high st immediately before 
parturition and lowest immediately after parturition.44 Taken together, these findings indicate that 
parturition affects immunity. It is hypothesized that in the study reported here, it was the effect of 
foaling that led to the low rate of virus isolation in the group 3 mares aftr vaccination. 
It is also important to consider the effects of the use of vaccines during pregnancy in 
other species. Pregnant sows vaccinated with an MLV vaccine for PRRSvirus, another member 
[in addition to EAV] of the family Arteriviridae, had a decreased number of pigs born alive and 
weaned, compared with results for pregnant sows that were not vaccinated.47 However, similar to 
the situation with EAV in naïve pregnant mares, this decrease in productivity is sometimes an 
acceptable alternative to the effects of disease caused by natural exposure to the PRRS virus. The 
reproductive performance of sows after vaccination against PRRS depends on the stage of 
gestation: the largest decreases in pigs born alive and weaned were detect d in sows vaccinated 
during the last 4 weeks of gestation,48 which again was similar to the most important reproductive 
dysfunction in the mares vaccinated during late gestation in the present study. In contrast to the 
results of these studies in pregnant sows vaccinated with a MLV vaccine against PRRS,47,48 it has 
been found that pregnant cows vaccinated with certain MLV respiratory vaccines did not have 
any detrimental effects.49 In that study,49 pregnant cows vaccinated throughout gestation with a 
combination vaccine containing MLV components against bovine herpesvirus-1, bovine viral 
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diarrhea virus, parainfluenza virus-3, bovine respiratory syncytial virus, and inactivated cultures 
of L interrogans serovars Canicola, Grippotyphosa, Hardjo, Icterohaemorrhagiae, and Pomona 
had abortion rates similar to those of pregnant cows and heifers administered steril  water diluent 
during the same stages of gestation. Therefore, effects of vaccination on reproductive 
performance of a pregnant animal appear to depend on the vaccine. 
Serologic results of the mares and foals in group 3 indicated that the mares became 
seropositive after vaccination, whereas the foals did not. Several reasons may have accounted for 
this, including the fact that when the mares developed vaccine-induced titers following 
vaccination 2 days after parturition, the foals were no longer able to absorb antibodies through the 
gastrointestinal mucosa. Transintestinal permeability for immunoglobulins of calves progresses to 
complete impermeability between 12 and 24 hours after birth, and foals have been found to have 
a similar time for gastrointestinal closure.50,51 Although 12 of 28 mares in group 3 shed vaccine 
virus, the amount of vaccine virus shed may have been too low to exceed the threshold do e 
needed to infect and result in seroconversion in the foals, except for 2 of the foals. 
Virus neutralization testing of milk samples revealed that the colostrum collected at 
foaling was antibody-positive for all mares in group 1. In group 2, all mares (except for 4) had 
positive results for antibodies against EAV in colostrums samples collected at foaling; the 4 
mares that had negative results were vaccinated 2, 4, 4, and 19 days before foaling, respectively. 
The milk obtained 12 hours after foaling from 3 of those mares (vaccinated 2, 4, and 4 days 
before foaling respectively) still had negative results, whereas the milk of the other mare had a 
titer of 1:32 (low positive titer), perhaps because the mare was vaccinated only 19 days before 
foaling. Milk samples from the other 3 mares probably had negative results because a sufficient 
amount of time had not elapsed between vaccination and sample collection; avalable serum 
samples obtained from these 3 mares at 0 and 12 hours also had negative results, whereas the 
serum samples obtained from these mares at 30 days after parturition had titers of≥ 1:512. 
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Analysis of the findings in the study reported here confirmed what has been the official 
recommendation for vaccination of peripartum mares with the MLV vaccine against EVA. 
Although vaccination of pregnant mares with MLV vaccines should be undertaken with caution, 
it appears that the risk of adverse consequences is minimal in mares vaccinated up to 3 months 
before foaling. Vaccination of these mares provides the potential benefit of colostral antibody 
protection for the foals, which does not appear to be evident in mares vaccinated soon after 
foaling. It is also apparent that mares may be vaccinated during the last 2 months of gestation and 
they will not necessarily abort; 16 of 19 mares in group 2 gave birth to healthy foals. I  mare 
populations are under stress or have been exposed to other infections, vaccination against EAV 
during the last 2 months of gestation may result in abortion. However, for most circumstances, 
the risk of abortion is less likely. On the basis of these findings, and in the face o  a high risk of 
natural exposure to EAV, the risk of vaccination-related abortion is faroutweighed by the 
substantial risk of EVA-related abortion and the potential of widespread dissemination of the 
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Footnotes 
a. Arvac, Fort Dodge Animal Health, Overland Park, Kan. 
b. Qiagen, Valencia, Calif. 
c. TaqMan RT-PCR assay, Applied Biosystems, Foster City, Calif. 
d. TaqMan One-Step RT-PCR Master Mix, Applied Biosystems, Foster City, Calif. 
e. 7500 Fast real-time PCR System, Applied Biosystems, Foster City, Cal f. 
f. MultiScribe Reverse Transcriptase, Applied Biosystems, Foster Ci y, Calif. 
g. RNase inhibitor, Applied Biosystems, Foster City, Calif. 
h. Oklahoma Animal Disease Diagnostic Laboratory, Oklahoma State Univ rsity, 
Stillwater, Okla. 
i. VRMD, Pullman, Wash. 
j. PC SAS, version 9.2, SAS Institute Inc, Cary, NC. 
k. PROC MIXED, PC SAS, version 9.2, SAS Institute Inc, Cary, NC.
38 
 
l. LSMEANS with SLICE, PC SAS, version 9.2, SAS Institute Inc, Cary, NC. 




TABLE 1: Day of vaccination relative to day of foaling for the mares used in the EVA 
vaccination study. 
         
 GROUP 1*  GROUP 2¥ GROUP 3§   
     








 Mare vaccination and Mare vaccination and Mare foaling and  
  No.      foaling (days) No.     foaling (days)  No. vaccination(days)   
 1 -141 23 -25 43    2  
 2 -130 24 -41 44    2  
 3 -131 25 -54 45    2  
 4 -114 26 -68 46    2  
 5 -129 27 -13 47    2  
 6 -118 28 -11 48    2  
 7 -113 29 -36 49    2  
 8 -85 30 -9 50    3  
 9 -91 31 -2 51    2  
 10 -129 32 -36 52    2  
 11 -123 33 -53 53    2  
 12 -83 34 -38 54    3  
 13 -122 35 -52 55    2  
 14 -107 36 -18 56    3  
 15 -101 37 -4 57    2  
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 16 -142 38 -4 58    2  
 17 -120 39 -19 59    2  
 18 -125 40 -11 60    2  
 19 -121 41 -40 61    2  
 20 -101   62    3  
 21 -96    63    2  
 22 -103    64    2  
       65    2  
       66    2  
       67    2  
       68    2  
       69    2  
       70    2  
          
        
        
*Group 1(n=22) vaccinated between 142-83 days before foaling. 
¥ Group 2 (n=19) vaccinated between 68-2 days before foaling. 









Table 2—Results of VN testing of serum and milk samples from the mars and foals in Group 1 
(mid-term prepartum vaccinates). 
 Mare No.  Milk VN Titer Serum VN Titer (Mare)   Serum VN Titer (Foal) 
  0h 12h 1m 0h 12h 1m 0h 12h 1m 
1 ≥1:512  1:128 <1:4  1:256  1:256  1:128 <1:4 ≥1:512  1:32 
2 ≥1:512  1:128 N/S  1:128  1:64  1:256 <1:4 ≥1:512  1:32 
3 ≥1:512  1:128 N/S  1:512  1:256  N/S <1:4 ≥1:512  N/S 
4 ≥1:512 ≥1:512  1:4  1:16  1:32  1:64 <1:4  1:16  1:32 
5 ≥1:512  1:32 <1:4  1:64  1:128  1:32 <1:4  1:256  1:64 
6 ≥1:512  1:256  1:4  1:64  1:128  1:128 <1:4  1:256  1:64 
7 ≥1:512 ≥1:512  1:32 ≥1:512  1:256 ≥1:512 <1:4  1:256  1:512 
8 ≥1:512  1:256 <1:4  1:128  1:128  1:64 <1:4 ≥1:512  1:32 
9 ≥1:512  1:64 <1:4 ≥1:512 ≥1:512 ≥1:512 <1:4 ≥1:512 ≥1:512 
10 N/S  1:256  1:4 ≥1:512 ≥1:512 ≥1:512 <1:4 ≥1:512 ≥1:512 
11  1:64  1:16 <1:4  1:128  1:128  1:256 <1:4  1:256  1:64 
12 ≥1:512  1:64 N/S ≥1:512  1:512  N/S <1:4 ≥1:512  N/S 
13  1:256  1:32 N/S ≥1:512 ≥1:512  N/S <1:4  1:128  N/S 
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14 ≥1:512  1:64  1:16 ≥1:512 ≥1:512 ≥1:512 <1:4 ≥1:512  1:128 
15 ≥1:512  1:128  1:8 ≥1:512  1:256  1:256 <1:4  1:256  1:128 
16 ≥1:512  1:128  1:8 ≥1:512 ≥1:512 ≥1:512 <1:4 ≥1:512 ≥1:512 
17  1:256  1:16 N/S  1:128  1:16  1:16 <1:4  1:64  1:4 
18 ≥1:512 ≥1:512  1:32 ≥1:512 ≥1:512 ≥1:512 <1:4 ≥1:512 ≥1:512 
19 ≥1:512  1:16 <1:4 ≥1:512  1:256  1:256 <1:4  1:64  1:32 
20 ≥1:512  1:64 <1:4 ≥1:512 ≥1:512 ≥1:512 <1:4  1:256  1:16 
21 ≥1:512  1:16 N/S  1:128  1:128  1:128 <1:4  1:128  1:4 
22 ≥1:512  1:64 N/S <1:4 ≥1:512  N/S <1:4 ≥1:512  N/S 
0h = Sampled at time of foaling. 12h = Sampled 12 hours after foaling. 1m = Sampled 1 month 
























Table 3—Results of VN testing of serum and milk from the mares and foals in Group 2 (late term 
prepartum vaccinates). 
Mare No.  Milk VN Titer Serum VN Titer (Mare)   Serum VN Titer (Foal) 
  0h 12h 1m 0h 12h 1m 0h 12h 1m 
23 ≥1:512  1:8 <1:4 ≥1:512  1:256  1:64 <1:4  1:256  1:32 
24 ≥1:512 ≥1:512 <1:4 ≥1:512  1:256 ≥1:512 <1:4 ≥1:512  1:256 
25  1:64  1:16 N/S  1:32  1:32  1:16 <1:4  1:32  1:16 
26 ≥1:512  1:32 N/S ≥1:512  1:256 N/S  1:16  1:256 N/S 
27 ≥1:512 N/S  1:16  1:128 N/S  1:256  1:4 N/S <1:4 
28 N/S N/S N/S N/S N/S N/S <1:4 N/S N/S 
29  1:256  1:256  1:4 ≥1:512  1:256  1:32 <1:4  1:32  1:16 
30 N/S N/S N/S N/S N/S N/S <1:4 N/S N/S 
31 <1:4 <1:4  1:256 <1:4 <1:4 ≥1:512 <1:4 <1:4 N/S* 
32 ≥1:512  1:256  1:8 ≥1:512 ≥1:512  1:256 ≥1:512 ≥1:512  1:64 
33 ≥1:512  1:64 <1:4  1:32  1:128  1:8 <1:4  1:256  1:16 
34 N/S ≥1:512 N/S N/S  1:64 N/S N/S N/S N/S 
35 ≥1:512  1:4 <1:4  1:64  1:128  1:32 <1:4  1:16 <1:4 
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36 ≥1:512  1:128 <1:4 ≥1:512 ≥1:512 ≥1:512 <1:4  1:128  1:32 
37 <1:4 <1:4  1:4 N/S <1:4 ≥1:512 <1:4 <1:4 <1:4 
38 <1:4 <1:4  1:16 <1:4 <1:4 ≥1:512 <1:4 <1:4 <1:4 
39 <1:4  1:32  1:8  1:64  1:32 ≥1:512 <1:4  1:16 <1:4 
40  1:64  1:16  1:4  1:64  1:128  1:256 <1:4 <1:4 <1:4 
41 N/S  1:256 N/S  1:128  1:256  1:256 <1:4  1:256 N/S* 
42A(control) <1:4 <1:4 <1:4 <1:4 <1:4 <1:4 <1:4 <1:4 <1:4 
42B(control) <1:4 <1:4 <1:4 <1:4 <1:4 <1:4 <1:4 <1:4 <1:4 
*Euthanized at approximately 1 month of age. 
0h = Sampled at time of foaling. 12h = Sampled 12 hours after foaling. 1m = Sampled 1 month 






















Table 4—Virus isolation and serologic results on the mares and foals in Group 3 (postpartum vaccinates). 
Mare no. VN titer (mare) VN titer (foal)  Virus isolation – buffy coat (mare) Virus isolation – nasopharyngeal sample (mare) 
 0d‡ 14d* 28d* 0d‡ 14d* 28d* -2d† 1d* 3d* 5d* 7d* 14d* 28d* 0d‡ 1d* 3d* 5d* 7d* 9d* 11d* 14d* 21d* 
43(P) <1:4 ≥1:512 1:256 <1:4 <1:4 <1:4 - - + N/S - - - - - N/S - - - - - - 
44(P) <1:4 ≥1:512 1:256 <1:4 <1:4 <1:4 - - - - -  N/S  N/S - + - - - N/S N/S N/S N/S 
45(P) <1:4 1:256 ≥1:512 <1:4 <1:4 <1:4 - - - - + - + - - - - - - - N/S - 
46(P) <1:4 1:128 ≥1:512 <1:4  N/S <1:4 - - - - - -  N/S - - - - - - - - - 
47(P) <1:4 ≥1:512 ≥1:512 <1:4 <1:4 <1:4 N/S - - - - - - - - - - - - - - - 
48(P) <1:4 ≥1:512 ≥1:512 <1:4  N/S <1:4 - - N/S - - -  N/S - - - - - - - - - 
49(P) <1:4 ≥1:512 1:256 <1:4  N/S <1:4 - + + - - - - - - - - - - - - - 
50(P) <1:4 1:256 1:128 <1:4 <1:4 <1:4 - - - - - - - N/S N/S - - - - - - N/S 
51(P) <1:4 1:128 1:64 <1:4 <1:4 <1:4 - - - - - - - - - - - - - - - - 
52(P) <1:4  N/S  N/S <1:4  N/S  N/S - + + - -  N/S  N/S - - + - - - N/S N/S N/S 
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53(P) <1:4 1:256 1:256 <1:4  N/S ≥1:512 - + - - - - - - - - - - - - - - 
54(P) <1:4 1:256 1:64 <1:4 <1:4 <1:4 - - - - - - - - - - - - - - - - 
55(P) <1:4 1:64  N/S <1:4 <1:4  N/S - - - - - -  N/S - - - - - - - - N/S 
56(P) <1:4 1:256  N/S <1:4 1:128  N/S - + - - - -  N/S - - - - - - - - N/S 
57(P) <1:4 1:8 1:64 <1:4 <1:4 <1:4 - - N/S Neg - - - - - - N/S - - - - - 
58(P) <1:4 1:128 1:256 <1:4 <1:4 <1:4 - - - + - - - - - - - - - - N/S - 
59(P) <1:4 1:256 ≥1:512 <1:4 <1:4 <1:4 - - + - - - - - - - - - - - - N/S 
60(S) <1:4 1:256 ≥1:512 <1:4 <1:4 <1:4 - - - - - - - - - - - - - - - - 
61(S) <1:4 1:256 1:128  N/S <1:4 <1:4 N/S - - - - - - - - - - - - - - - 
62(S) <1:4 1:256 1:256 <1:4 <1:4 <1:4 N/S N/S - - - - - - - - - - - - - - 
63(S) <1:4 ≥1:512 1:256 <1:4 <1:4 <1:4 - + - - - - - - - + - - - - - - 
64(S) <1:4 ≥1:512 ≥1:512 <1:4 <1:4 <1:4 - - - - - - - - - - - - - - - N/S 
65(S) <1:4 ≥1:512 ≥1:512 <1:4 <1:4 <1:4 - - - - - - - - - + - - - - - N/S 
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66(S) <1:4 1:256 1:256 <1:4 <1:4 <1:4 - - - - - - - - - - - - - - - - 
67(S) <1:4 1:32 1:64 <1:4 <1:4 <1:4 - - - - - - - - - - - - - - - - 
68(S) <1:4 ≥1:512 1:256 <1:4 <1:4 <1:4 - - - - - - - - - + + - - - - - 
69(S) <1:4 1:128 1:256 <1:4 <1:4 <1:4 - - - - - - - - - - - - - - - - 
70(S) <1:4 1:256 1:256 <1:4 <1:4 <1:4 - - - - - - - - - - - - - - - N/S 
71(PC) <1:4 <1:4 <1:4 <1:4 <1:4 <1:4 - - - - - - - - - - - - - - - - 
72(SC) <1:4 <1:4 <1:4 <1:4 <1:4 <1:4 - - - - - - - - - - - - - - - - 
*Days post-vaccination of mares. †Days pre-vaccination of mares. ‡Day of v ccination of mare. 










EMBRYO TRANSFER STUDY ABSTRACT 
 
The objective was to evaluate the potential risks associated with embryo transfer 
from mares bred with equine arteritis virus (EAV) infective semen. Twenty-six mares 
were embryo donors, whereas 18 unvaccinated and EAV antibody seronegative mares 
were embryo recipients. Of the 26 donor mares, 15 were unvaccinated and seronegative 
for antibodies to EAV and 11 were vaccinated for the first time with a commercially 
available modified live virus vaccine against EVA before breeding and subseq ent 
embryo transfer. All donor mares were bred with EAV-infective semen from a stallion 
persistently infected with the virus. Twenty-four embryos were recovered 7 d post-
ovulation; all were subjected in sequential order to five washes in embryo flush medium, 
two trypsin treatments, and five additional washes in embryo flush medium (prior to 
transfer). Twelve and seven embryos (Grades 1 or 2) were transferred from the non-
vaccinated and vaccinated donors, respectively, and pregnancy was established in 3 of 12 
and 2 of 7. Perhaps trypsin reduced embryo viability and pregnancy rate. The uterine 
flush fluid of 11 mares (9 of 15 and 2 of 11 from non-vaccinated and vaccinated donor 
groups, respectively) was positive for EAV by VI (confirmed by real-time RT-PCR); the 
wash fluid from the embryos of nine of these mares was negative following 10 washes
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and two trypsin treatments. However, the embryo wash fluid from two mares was still 
positive for EAV after all 10 washes and the two trypsin treatments, and one embryo was 
positive for EAV. Two of 18 recipient mares had seroconverted to EAV 28 d after 
embryo transfer. Virus was not detected in any fetal tissues or fluids harvested after 
pregnancies were terminated (60 d). In conclusion, we inferred that the washing protocol 
of 10 washes and two trypsin treatments did not eliminate EAV from all embryos; due to
limitations in experimental design, this requires confirmation. Furthermore, there may be 
a risk of EAV transmission associated with in vivo embryo transfer from a donor mare 






EMBRYO TRANSFER STUDY INTRODUCTION 
 
Equine viral arteritis (EVA) is a contagious disease of equids caused by quine arteritis 
virus (EAV). Although the majority of primary cases of EAV infection are subclinical and 
consequently undetected, some outbreaks may be associated with the appearance of influenza-like 
clinical signs, abortion in pregnant mares, and interstitial pneumonia in eonatal foals [1,2]. The 
risk of abortion in pregnant mares and the potential for persistent infectio  in stallions have 
substantial economic ramifications for the horse breeding industry. Equine arteritis virus is an 
enveloped RNA virus belonging to the family Arteriviridae, which also includes another 
important viral disease, porcine reproductive and respiratory syndrome (PRRS) [3,4]. These 
viruses are readily inactivated by common disinfectants and detergents. Equine arteritis virus 
survives for just 2 to 3 d at 37 °C, although it may survive up to 75 d at 4 °C [5].  
 Equine viral arteritis is a disease of worldwide concern, with serologic evidence of 
infection being reported in North and South America, Europe, Australia, Africa, and Asia [1,6]. 
However, the seroprevalence of EAV infection varies greatly between countries and among 
equine populations within countries. The 1998 National Animal Health Monitoring System 
(NAHMS) equine survey reported only 2.0% of unvaccinated horses in the United Stat s were 
seropositive to EAV, in contrast to horses imported into California having a seropositive rate of 
18.6% (mostly European Warmbloods) [7,8]. The seroprevalence of EAV infectio  varies widely
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between breeds in the USA, with approximately 80% of Standardbreds and 5.4% of 
Thoroughbreds antibody positive. Most other breeds are believed to have a seroprevalence of 
<2% [1,9-13]. Differences in prevalence between breeds may in part be associated with 
differences in management practices. This was exemplified during the extensive outbreak of EVA 
in Thoroughbreds in Kentucky in 1984 [14] and in the more recent multistate occurrence in 
Quarter Horses in the USA in 2006-2007 [6,15,16]. 
Transmission of EAV between horses principally occurs via the respiratory nd/or 
venereal routes [1,17-20]. Outbreaks have frequently resulted from breeding a naïve mare with 
EAV infective semen; the virus is subsequently disseminated to other naïve animals on the 
premises by the respiratory route. Naturally infected stallions may become persistent carriers of 
EAV. Establishment and maintenance of the carrier state is testosterone-dependent, with the virus 
localized to the accessory sex glands [21,22]. Persistently infected stallion  may be short term (<3 
mo), intermediate (3-7 mo), or long term carriers (7 mo to several years) [18,22]. Carrier stallions 
can play a major role in the widespread dissemination of the infection and are the primary natural 
reservoir of the virus [1,6,9]. 
In addition to the acknowledged risk of spread of EAV via semen, embryo transfer (ET) 
must also be considered as a potential route of spread. Equine arteritis virus present in 
reproductive tract secretions of naturally infected mares [23], and these secretions are in contact 
with the developing embryo until it is collected from the donor mare approximately 7 d after 
breeding [24]. With the increasing number of ET being performed in some breeds, this procedure 
may pose a risk of transmission of EAV which has not been adequately determined.  
Numerous studies have been conducted on the efficacy of various disinfection procedures 
for controlling microorganisms in the semen and embryos of humans and farm animals. Methods 
described include washing procedures, enzymatic treatments, antibiotics, immunological 
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methods, photosensitive dyes, antiviral agents, interferon, lactoferrin, and acidification [25]. One 
of the most common methods of disinfecting embryos involves trypsin; the method is detailed in 
the Manual of the International Embryo Transfer Society (IETS) [26]. Althoug trypsin 
effectively removed most bacteria and some viruses from embryos, it was neffective in removing 
African swine fever virus and bovine mycoplasmas from in vivo-derived embryos [27-29]. It also 
failed to inactivate equine encephalomyelitis virus and swine influenza virus in infected cell 
cultures [30]. It is important to note that transmission of any virus throug the ZP into the oocyte 
by the fertilizing sperm has not been reported in either cattle or horses [31]. With respect to the 
international shipment of bovine embryos, the risks from enzootic bovine leukosis viru , bovine 
herpesvirus-1, and bluetongue virus infective semen are negligible when embryos are processed 
in accordance with the IETS protocol. However, there is the potential that in vivo-derived 
embryos resulting from breeding with bovine viral diarrhea virus infectiv semen may still be 
contaminated with the virus [32]. A recent study indicated that bovine embryos, when washed 
according to the IETS guidelines, do not cause BVDV transmission to recipients or their 
offspring [33]. 
Equine embryos were treated with trypsin in several studies. In experiments involving 
embryo cryopreservation, trypsin increased the permeability of the capsule [34,35]. Trypsin also 
made the capsule more prone to loss during subsequent embryo handling; furthermore, absence of 
the capsule was detrimental to embryonic survival in vivo [36,37]. Trypsin has been used 
experimentally to successfully remove EHV-1 from exposed equine early blastocysts, whereas 
washing alone without trypsin did not successfully remove EHV-1 from embryos; however, 
neither study involved subsequent ET [38,39]. In contrast to its effectiveness on arly blastocysts, 
trypsin did not decontaminate EHV-1-exposed expanded blastocysts or embryos surrounded only 
by the capsule [40]. 
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It is not currently known whether EAV can be transmitted via ET. Therefore, the present 
study was conducted to assess the risk of transmission of infection associated with ET from non- 
EVA-vaccinated, as well as vaccinated donor mares, bred with EAV infective semen, and 
whether the internationally accepted protocol for washing embryos would succes fully prevent 






EMBRYO TRANSFER STUDY MATERIALS AND METHODS 
 
 Subjects and vaccination  
A total of 44 mares were selected as embryo donors or recipients and used in the study. 
The large number of available mares facilitated the synchronization of embryo donors with 
embryo recipients. Synchronized mares were randomly allocated into two groups. Twenty six 
were selected as embryo donor mares, and 18 as embryo recipients. A single serum sample was 
obtained from each mare prior to vaccination or placebo treatment to confirm their seronegativity 
for antibodies to EAV. Donor mares were also tested for serum neutralizing antibodies to EAV on 
the day they were bred. Of the 26 donor mares, 15 were not vaccinated against EVA (Group D) 
and 11 were vaccinated for the first time before breeding and subsequent embryo transfer (Group 
VD). Mares in the VD group were given their first vaccination with a modified-live virus EVA 
vaccine (Arvac® , Pfizer Animal Health, New York, NY, USA) 28 d prior to being bred with 
virus infective semen (Day -28). Mares in the D group were administered a single placebo IM 






 This study was approved and conducted in accordance with the guidelines of th  
Oklahoma State University Institutional Animal Care and Use Committee. All mares were 
maintained at the Center for Veterinary Health Sciences Ranch (CVHSR) in Stillwater, OK, USA 
for the duration of the study. These mares did not have contact with any EAV infected or exposed 
mares. When ovulation was imminent and the decision made to breed each donor mare, she was 
moved by trailer (observing standard biosecurity procedures) to a separate research facility 
isolation area, 1 km away, which was accessible by a separate entranc. The isolation area 
consisted of four individual paddocks (20 m x 40 m), separated from each other by a 5 m alley;
each paddock had separate water and feed facilities. Recipient mares were moved to a separate 
paddock in this isolation area when they were considered ready to receive an embryo. Mares bred 
with EAV-infective semen were maintained separately from the recipient mares and there was no 
risk of indirect viral transmission via fomites. All recipient mares were placed in paddocks not 
previously occupied by EAV exposed mares. 
 
 Mare reproductive management 
Each non-vaccinated mare was artificially inseminated with EAV infectiv  semen and the 
recovered embryos were transferred to seronegative recipients. Once Group D was complete, the 
remaining mares selected as embryo donors were vaccinated against EVA and served a  the VD 
group. 
The estrous cycles of all mares within each group were synchronized as closely as 
possible with prostaglandin (10 mg dinoprost given im) administered to mares with a CL that was 
at least 6 d post-ovulation. Most mares began to exhibit estrus 4-7 d after prostaglandin treatment 
and individual mares were then examined for cycle synchrony. Ultrasonography w s performed 
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daily on all mares once a follicle greater than 30 mm was detected. When the dominant follicle 
was >35 mm in the presence of diminishing endometrial edema and a softening cervix, either 
2500 IU human chorionic gonadotropin (Intervet-Schering Plough, Millsboro, DE, USA) or 1.1 
mg deslorelin (Essential Pharmacy Compounding, Omaha NE, USA) was administered to induce 
ovulation. Mares selected to serve as embryo donors were bred (24 h after hCG/deslorelin 
injection) with fresh chilled semen that was shipped by overnight delivery. Mares were moved to 
the isolation facility before they were bred. Both inseminated donor mares and potential recipient 
mares continued to be examined by ultrasonography to document the day of ovulation, with 
ultrasound examination for ovulation of bred mares being performed in the afternoon. The 
ultrasound machine and stocks used for mare restraint were thoroughly cleaned and disinfected 
with 1-Stroke Environ (Steris Corporation, St. Louis, MO, USA) between mares. Th  majority of 
mares ovulated 24-48 h after hCG or deslorelin injection, thus allowing multiple mar s to ovulate 
within several days of each other.  
In addition to the routine breeding described above, selected mares were treated with a 
superovulation protocol to increase the potential yield of embryos recovered. Mares were selected 
for this protocol depending on their individual cycle characteristics. Mares that had three or more 
follicles between 20 and 25 mm in diameter were selected to receive eFSH and undergo 
superovulation; mares that did not have a cohort of follicles did not receive superovulatory 
hormones, as there was minimal benefit in doing so. For mares that were select d for 
superovulation, ultrasonographic evaluations were performed daily, starting 5 d after ovulation, 
looking for the presence of multiple small follicles on both ovaries measuring approximately 20-
25 mm that developed in response to endogenous FSH. When the largest follicle(s) in the cohort 
attained a diameter of 23 to 25 mm, eFSH therapy was started. A dose of 12.5 mg eFSH was 
given im every 12 h for approximately 3-4 d. On the second day of eFSH therapy, prostaglandin 
(10 mg dinoprost) was given. The eFSH therapy was discontinued when >50% of the cohort of 
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developing follicles were approximately 35 mm in diameter. Mares were th n allowed to ‘coast’ 
without any hormone therapy for 24 h, and then given hCG (2,500 IU, IV) or deslorelin (1.1 mg), 
inseminated 24 h post hCG administration (Day 0), and monitored to determine day(s) of 
ovulation. A majority of mares with multiple ovulations had synchronous (i.e. same d y) 
ovulations. Occasionally a mare ovulated one or more follicles one day and one or more follicles 
the next day.  
The NV and VD groups of donor mares were exposed to EAV by insemination with 
extended semen from a known carrier stallion of proven fertility containing i fectivity titers >1 x 
105 plaque-forming units of EAV/mL of seminal plasma (Gluck Equine Research Center, 
Lexington, KY, USA). This virus has been sequenced and identified as EAV S3699 strain 
(GenBank Accession # GQ903796) [15]. The fresh chilled extended semen was stored at 
approximately 4 ⁰C and shipped from the farm of origin to the CVHSR by overnight delivery as 
needed for each mare. Upon arrival, sperm motility and morphology were assessed; every sample 
of extended semen received had >50% progressive motility and >90% normal morphology at 
insemination. Each mare to be inseminated was inseminated once with the shipped semen on the 
morning it was received. 
 
 Embryo recovery, sampling, and transfer 
Embryos were obtained by flushing the uterus 7-8 d after ovulation (Days 7 or 8 post 
insemination/virus exposure), using a commercial equine embryo flush solution (Emcare, Bio-
Free, Auckland, New Zealand). Embryo flushing was performed in the afternoon 7 d after 
ovulation was documented (also in the afternoon). Six liters of pre-warmed (35-37 oC) flush 
solution were used to recover embryos. The uterus was infused with 1 to 2 L of the s lution by 
gravity flow (via a 50 cm 37 french balloon tipped silicone catheter), then flushed back via 
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gravity flow out through a 75 µm in-line filter positioned above a 1 L collection cylinder (Partnar 
Animal Health, Port Huron, MI, USA). The process was repeated two or three additional times 
for a total of 6 L of flush solution per attempted embryo recovery. Recovery of fluid rom the 
second and third uterine lavages was assisted by transrectal massage of the uterus. After the last 
of the medium was recovered, the fluid within the filter cup was poured into three or four sterile 
search dishes and some unused flush solution was used to rinse the filter into the search dishes. 
The medium contained in the search dishes was then examined under 7-15x magnification with a 
stereo dissection microscope. Embryos were measured using an eyepiece micrometer and 
designated by size < or > 200 µm and deemed as Grades 1 to 4 (1 = excellent, 2 = good, 3 = fair, 
and 4 = degenerated and nontransferable). Separate flush kits were used for each mare, including 
autoclaved catheters and disposable tubing and filters. 
All collected embryos were washed according to the guidelines set out by the IETS [26]. 
Briefly, the washing protocol entailed 12 washes using 12 dishes (35 mm in diameter), each 
containing 2 mL of wash fluid. Washes 1-5 and 8-12 used fresh medium identical to that used to 
flush the embryos from the uterus. Proteolytic enzyme treatment between flush medium Washes 5 
and 8 consisted of 2 washes (Washes 6 and 7) in Hank’s balanced salt solution (pH 7.6 to 7.8) 
containing 0.25% porcine derived trypsin (Gibco, Carlsbad, CA, USA), with a total contact time 
of 60 to 90 s (~30 s per wash). Separate sterile micropipettes were used betw en wash wells, and 
the ambient temperature during treatments was approximately 27 oC. No more than 10 µL of 
wash medium containing the embryos (ensuring a 1:200 dilution) was transferred from one dish 
to another. If more than one embryo was collected from a mare, all embryos were washed 
together. Using a stereo microscope, all embryos were deposited at the 6 o’clock position in each 
dish, the embryos counted, each wash dish gently swirled counter-clockwise to fully disperse and 
disaggregate the embryos, and then very gently swirled in a clockwise direction depositing the 
embryos to the center of the dish. At the end of the wash procedure all embryos were examined 
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for defects within the zona pellucida (ZP) if present and graded for quality (1 = excellent or good, 
2 = fair, 3 = poor, and 4 = dead or degenerating) according to the IETS standard [41]. Both ZP 
intact Grades 3 or 4 embryos and ZP defective embryos from each individual mare were grouped 
separately. In the case of large expanded blastocysts, the ZP became very thin, but he spherical 
nature of embryo and the lack of an expanded capsule were used as an indication that 
disappearance of the ZP had not occurred [42,43]. 
The embryo flush medium was filtered through a 0.45 µm filter (Partnar Animal Health) 
and the filtrate tested for infectious virus in cell culture. Similarly, Washes 1, 3, 5, 8, 10, and 12 
were analyzed for the presence of virus in cell culture. Grades 1 or 2 embryos were transferred to 
seronegative recipient mares. Each recipient was donor matched according t  estrous cycle 
synchrony and received one or two embryos from that donor (in some cases, there were not 
enough synchronized recipients available to accept more than one embryo transfer). When only 
one Grade 1 or 2 embryo was flushed from a donor mare, that embryo was transferred to a 
recipient. If two such embryos were recovered, one was transferred and one was harvested for 
examination for virus. If three or more Grades 1 or 2 embryos were recovered, no more than two 
embryos were transferred to one recipient; the remaining embryo(s) were either transferred to a 
second recipient or harvested for virological examination.  
Grades 1 or 2 washed embryos were individually or doubly loaded into a 0.25 mL straw 
and transcervically transferred via a sheathed Cassou pipette and deposite  into the lumen of the 
uterine body, or base of the uterine horn of an individual embryo recipient mare. The straw was 
checked before transfer via microscopy and after transfer by flushing the catheter tip and 
subsequent microscopic examination to ensure transfer of the embryo had occurred. Recipients 
were selected that had ovulated 1 d prior (+1) to 3 d after (0, -1, -2, and -3) the donor mare, with 
highest preference given to recipient mares that ovulated 2 d after the donor mares, followed by 




 Pregnancy monitoring  
Embryo recipient mares were examined via transrectal ultrasonography for pregnancy at 
7 to 10 d post-transfer. The transducer was routinely cleaned with 70% isopropyl alcohol between 
examinations. Recipient mares were examined twice weekly via ultrasound to assess pregnancy 
status. If at any point the pregnancy was determined to be failing based on ultrasonographic 
appearance, the uterus was lavaged and the fluid tested for EAV. At 60 d gestation, all 
pregnancies were terminated via cervical dilation and uterine lavage with 2-6 L of saline. The 
fetus, fetal membranes, and allantoic and/or amniotic fluid were collected, frozen, and 
subsequently analyzed after initially making a tissue suspension when needed for viral infectivity 
by attempted isolation in RK-13 cells. 
 
 Monitoring of body temperature and clinical signs of embryo donor mares 
Rectal temperatures were obtained on embryo donor mares on Days 0-14 and 28 (Day 0 
= day of insemination with EAV-infective semen). Clinical signs in the embryo donor mares were 
also monitored and recorded on the same days, assessing the demeanor of the mares and noting 
the presence of any swelling or nasal discharge. 
 
Statistical analysis 
All statistical analyses were conducted using PC SAS Version 9.1 (SAS Institute, Cary, 
NC, USA). Analysis of variance procedures (PROC MIXED) were performed to assess the 
combined effects of day and vaccination on temperature. A repeated measures model was used, 
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with animal as the experimental unit for vaccination and day as the repeated factor. An 
autoregressive period 1 covariance structure was used to model the within an mal variation. The 
simple effect of vaccination for each day was assessed (SLICE option in an LSMEANS 
statement) and P-values reported. Means and SEM for each day and vaccination ombination 
were calculated and a significance level of 0.05 was used for all comparisons. 
 
 Virus isolation 
The following samples were collected from each donor mare for attempted virus isolation 
(VI): nasopharyngeal swabs, vaginal swabs, and whole blood samples for buffy coat harvest on 
Days 0, 7, 14, and 28 (relative to AI). In addition, uterine flush samples, embryo wash samples, 
nontransferable embryos, and semen samples were subjected to VI testing. Virus isolation was 
attempted in RK-13 cells according to the standard OIE protocol [44]. Briefly, whole blood 
samples collected into tubes containing EDTA anticoagulant were centrifuged at 500 x g for 10 
min. The plasma and buffy coat cells were aspirated and placed in 15 mL conical e trifuge 
tubes. The buffy coat cells were pelleted at 1500 x g for 10 min at 4 ⁰C. Plasma was aspirated, 
and the white blood cell pellet was re-suspended in 5 mL of EMEM (Oklahoma Animal 
Diagnostic and Disease Laboratory). The cell suspensions were frozen at -80 ⁰C until VI could be 
attempted. The nasopharyngeal swabs in viral transport medium were well vortexed before being 
filtered through a 0.45 µm syringe filter. Filtrates were frozen at -80 ºC pending virus isolation. 
Nontransferable embryos were frozen in embryo flush medium at -80 ⁰C until VI could be 
attempted. Virus isolation from PBMCs, nasopharyngeal swab filtrates, vaginal swab filtrates, 
nontransferable embryos, and clarified 10% fetal tissue suspensions was attempted in both high 
and low passage RK-13 cell lines, according to the OIE recommended protocol [43]. Briefly,
serial decimal dilutions (10-1 to 10-3) of each sample were made in supplemented EMEM and 1 
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mL of each dilution was inoculated into each of 2 × 25-cm2 flasks containing confluent 
monolayers of RK-13 cells. Flasks were incubated at 37 °C for 1 h before being overlaid with 
EMEM supplemented with 0.75% carboxy methyl cellulose. Flasks were incubated at 37°C and 
checked for the appearance of viral cytopathic effect (CPE) on postinoculati n Days 3 and 4. If 
there was no detectable CPE, a second blind passage was performed on Day 4. The RK-13 cell 
monolayers were fixed and stained with a 1% crystal violet solution containing 1% formaldehyde 
on post-inoculation Day 5 in the case of the first passage and on postinoculation Day 4 in the case 
of the second passage in cell culture. Tissue culture fluid (TCF) was harvested and stored at -80 
°C for viral RNA extraction. 
 
Viral RNA extraction and real-time Taq-Man® RT-PCR 
Viral RNA was directly isolated from VI-positive TCF samples using a commercial kit. 
Briefly, TCF samples were microcentrifuged at 13,800 g for 2 min, and 140 µL of supernatant 
was removed and used for nucleic acid extraction according to the manufacturer’s instructions 
(Quiagen viral RNA kit, Quiagen, Valencia, CA, USA). Viral nucleic acid was eluted in 60 µL of 
nuclease free water and stored at -80 °C.  
A one-tube, real-time TaqMan RT-PCR assay was performed using the TaqMan One-
Step RT-PCR Master Mix in a 7500 Fast Real-Time PCR System (Quiagen viral RNA kit, 
Quiagen). The primer and probe set used in the assay was identical to that previously described 
[45,46]. Every sample was tested in duplicate. Briefly, 25 µL of RT-PCR mixture for each 
reaction contained 12.5 µL of 2 × Master Mix without UNG (uracil-N-glycosylase), 40 × 
MultiScribe and RNase Inhibitor Mix, 900 nM of forward and reverse primers (0.45 µL), 250 nM 
probe (0.625 µL), nuclease free water (5.35 µL), and 5 µL of test sample RNA. The following 
thermocycling conditions were used under standard mode as per manufacturer’s recommendation: 
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30 min at 48 °C, 10 min at 95 °C, followed by 40 cycles at 95 °C for 15 s, and 60 °C for 1 min. 
Each RT-PCR run included a negative control without RNA (containing the reaction mix with 5 
µL of water [no template control]) and positive controls. The sensitivity of this assay was 10 
RNA molecules [45,46]. 
 
Virus neutralizing titers 
Upon arrival at the research facility, blood was collected from each mre to document 
that it was negative for neutralizing antibodies to EAV. In the course of the experiment, blood 
was collected from each donor mare by jugular venipuncture on 0, 7, 14, and 28 d postbreeding, 
allowed to clot, and the serum harvested for testing for antibodies to EAV. Blood was also 
collected from each recipient mare 14 and 28 d post embryo transfer, and serum teted to 
determine if seroconversion had occurred. Sera were screened for neutralizing antibodies to EAV 






EMBRYO TRANSFER STUDY RESULTS 
 
Embryo collection and transfer  
Of the 26 embryo donor mares in this study, embryo recovery was not attempted on one 
mare in the non-vaccinated group, due to Grade 2 fluid accumulation in the uterus on 7 d after AI. 
A total of 24 embryos were obtained from the remaining 25 embryo donor mares. Sixteen 
embryos were recovered from 11 of the remaining 14 mares in the non-vaccinated group. Seven 
of the 11 vaccinated donor mares yielded a total of eight embryos upon uterine flushing. Embryo 
transfer results are summarized in Tables 2 and 3. 
 Of the 16 embryos obtained from the non-vaccinated group, 12 were transferred into 11 
recipients (one recipient received two embryos). Four embryos were of unsatisfactory quality to 
transfer and were frozen for laboratory testing. Of the eight embryos obtained from the 
vaccinated group, seven were transferred into seven recipients, and one embryo was frozen for 
laboratory testing. 
 
Resultant pregnancies of transferred embryos 
Of the 11 mares receiving embryos obtained from the non-vaccinated donor mare group, 
three were pregnant at Day 14. One of these pregnancies, in mare R11, was lost between Days 14
65 
 
and 24 (when she was subsequently examined). Fluid and tissues were recovered for vi us 
isolation and rRT-PCR testing by uterine lavage when this pregnancy was noted to be failing. The 
other two pregnancies continued to be monitored and were allowed to progress to 60 d, at which
time they were terminated and the fetuses and uterine fluid collected for diagnostic testing. 
 Of the seven mares receiving embryos from the EVA vaccinated donor mare group, two 
(mares R12 and R16) were pregnant at Day 14. Mare R16, though pregnant at 14 d, had lost t e 
pregnancy by Day 21, at which time uterine lavage was performed to collect embryonic tissue 
and fluid for virus isolation and rRT-PCR. Mare R12’s pregnancy progressed until 60 d, at which 
time the pregnancy was terminated and the fetus and uterine fluids were coll cted for diagnostic 
testing. 
  
Body temperature results and assessment of clinical signs in embryo donor mares 
 Mean body temperatures of the non-vaccinated donor mares were significantly higher 
than the mean temperatures of the vaccinated donor mares on Days 2, 4-11, and 28. Mean
temperatures of the two groups displayed the greatest difference on Days 6, 7, and 8, with non-
vaccinated mares demonstrating mean temperatures of >1.1 ⁰C higher than vaccinated mares on 
those days (Fig. 1).  
Clinical signs suggestive of EVA were seen in conjunction with the elevat d 
temperatures in many of the donor mares, both in those that were vaccinated as well as those not 
vaccinated against EVA. Clinical signs were more severe in nonvaccinated m r s; nasal 
discharge was observed in 12 of 15 mares, with moderate to severe mucopurulent nasal discharge 
noted in 5/15 mares. Three of 15 mares in the non-vaccinated group displayed minimal swelling 
of their rear legs for 1-2 d. None of the non-vaccinated mares had swollen extr mities on Day 28. 
In the vaccinated group, serous nasal discharge was noted in 6/11 mares on one or more days; 
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however, none of the mares developed a mucopurulent nasal discharge. None of the mares in the 
vaccinated group displayed any swelling of the extremities. 
 
Virus detection and serologic results on semen and embryo donor mares 
Six aliquots of semen were collected and frozen from the EAV carrier stallion over the 
period of the study to confirm his infectivity. All six samples from the stallion were EAV positive 
by VI and PCR. 
All fetal tissues, allantoic, and amniotic or fetal wash fluids from the fetuses and fluids 
collected from the three 60-d pregnancies, as well as the flush fluid and tissues from the two 
mares that lost their pregnancies between Days 14 and 21 were negative for EAV by VI. 
 All mares in the non-vaccinated donor mare group were negative for antibodies t  EAV 
on Day 0 (day of AI with EAV-infective semen). Thirteen of the 15 mares in the non-vaccinated 
group were seropositive by 28 d following insemination (Table 1). The majority of the mares that 
seroconverted did so by Day 14, although Mares D1 and D3 had not seroconverted by Day 28 
after insemination. While these mares exhibited mucopurulent nasal discharge approximately 4-7 
d post breeding, neither became febrile. 
 Based on attempted VI, 9 of 15 mare in the non-vaccinated group were positive for EAV 
from the buffy coat on Day 7 after AI, 8 of 15 were virus positive from nasal swab filtr tes, and 
eight were EAV positive from vaginal swabs on post-insemination Day 7. Vaginal swabs from all 
the mares were virus negative on Day 0 (prior to breeding); a Day 0 sample was not available on 
Mare 13. Overall, 12 of 15 mares were positive by VI on either buffy coat, nasopharynge l swab, 
or vaginal swab on either Days 7 or 14 post-insemination. All donor mares were VI negative on 
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buffy coat, nasopharyngeal swab, and vaginal swab by Day 28 following insemination. All virus 
positive results were confirmed by PCR assay (Table 1). 
 All 11 mares in the EVA vaccinated group of donor mares were positive for antibodies to 
EAV on the day of insemination. Titers ranged from 1:8 to ≥1:512. From Day 14 to the end of the 
test period (Day 28), all mares in this group had developed titers ≥1:512.  
 No infectious virus was detected in the buffy coat samples of mares in the VD group over 
the duration of the sampling period. Two of 11 nasopharyngeal swab samples were positive for 
EAV on attempted VI, one on Day 14 (mare VD20), and one on Day 7 (mare VD24). Four of 11 
vaginal swab samples were EAV positive on Day 7. Buffy coat, nasopharyngeal swab, and 
vaginal swab specimens collected 28 d after insemination were VI negative. Positive VI results 
were confirmed by PCR assay (Table 1). 
 
 Embryo recipient serologic testing  
All recipient mares that were blood sampled (samples were unavailable from two mares) 
were seronegative 14 d following embryo transfer. Of 18 mares sampled 28 d after embryo 
transfer, 16 of 18 were seronegative for antibodies to EAV. However, two mares, numbers R2 
and R13, were seropositive 28 d following embryo transfer, with titers of 1:16 and 1:64 
respectively (Table 2). 
 
 Virus detection results on embryo flush and wash samples  
Virus isolation was performed on embryo collection (flush) fluids, the wash fluids, and 
the embryo itself, if it was not of satisfactory quality to be transferred. Nine of 15 flush fluid 
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samples from mares in the non-vaccinated group were positive for EAV by VI and PCR. Of the 
embryos recovered and washed from 11 mares, four of the wash fluid samples were virus positive 
after the first wash, and one was positive beginning with Wash five. Three samples of embryo 
wash fluid became negative starting with Wash 3 and remained negative through the rest of the 
washes. The wash fluid samples from two embryos from mares D3 and D4 were virus-positive in 
the case of Washes 5, 6, and 10. The embryo from mare D3 which was not transferred was 
negative for virus, whereas the embryo from mare D4 which was also not transfer ed was positive 
by VI and PCR.  
 Two of 11 flush fluid samples from the vaccinated donor mares were positive for EAV 
by VI and PCR. No embryo was recovered from Mare VD24. An embryo was recovered from 
Mare VD19, and all the washes were negative for EAV by VI. This embryo was transferred into 






EMBRYO TRANSFER STUDY DISCUSSION 
 
Embryo transfer (ET) in horses has become increasingly popular over the last d c de, in part 
due to the easing of breed registration restrictions. The American Quarter Ho se Association, for 
example, now permits registration of foals born as a result of embryo transfer. Another factor 
influencing the growing popularity of equine ET is the increased success of ET, in large measure 
due to improved technical proficiency of the veterinarians performing the proc dure. In light of 
the popularity of embryo transfer, especially in the American Quarter Horse (AQH) breed, and 
the multistate occurrence of EVA involving the breed in 2006/07 [6,15,16], the risks of 
performing embryo transfer from a mare that has been bred with EAV-infective semen needed to 
be investigated. Efforts were made in this study to simulate the natural conditions that a mare 
would experience when bred with virus-positive semen. 
The ability of the wash and trypsin treatment protocol to remove infectious virus from the 
embryos was assessed in two ways: (1) sampling and testing of the wash fluid; and (2) 
determining whether the embryo recipient mares seroconverted to EAV. That EAV was present 7 
d after ovulation in the reproductive tracts of the majority of the NV group mares was a very 
important result, with 9 of 15 flush samples from this group virus positive by VI and PCR. 
Moreover, the rate of dilution of virus in those flushes would be high, making it remarkable that 
virus detection was positive. For flushes reported to be negative, perhaps the quantity of virus in 
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the flush was too low to be detected by methods used in this study. Regarding the VD group, 2 of 
11 flush samples tested positive 7 d after ovulation; therefore, we inferred that vaccination 
reduced the frequency of EAV in the reproductive tract of vaccinated mares. Of the total of 18 
washes/trypsin treatments (if multiple embryos were collected, they were washed/trypsin treated 
together), four samples from wash one were positive by VI and PCR, two of which ere negative 
on subsequent washes. All four samples were from mares in the non-vaccinated group. Two 
samples continued to be virus positive up to and including Wash 10; neither embryo was of 
sufficient quality to transfer, therefore both were tested by VI and PCR, with one of the two 
testing positive. Therefore, we inferred that the wash protocol including trypsin treatment was not 
successful in all cases in removal of EAV from the embryo. 
 The second measure by which the ability of the wash and trypsin protocol to remove 
infectious virus from the equine embryo was assessed also confirmed ineffectiv ness of the 
protocol in every case. Of the 18 mares in which embryos were transferred, all were seronegative 
on Day 14 post transfer; 16 were still seronegative on Day 28 post transfer, i dicating that in most 
cases, the transfer of a washed and trypsin treated embryo did not result in EAV infection. 
However, two of the 18 recipient mares did seroconvert, indicating that EAV can be transmitted 
by embryo transfer, even when the embryo has been subjected to the accepted IETS wash and 
trypsin treatment protocol. Both of the seropositive mares received embryos derived from mares 
whose uterine flush fluid tested positive for EAV by PCR and VI, although virus was not detected 
in any of the washes of these two embryos. Perhaps the virus was tightly adherent to the embryo 
and could not be removed by the wash and trypsin treatment; it is also possible that the amount of 
available virus in the wash fluid was so small that it was undetectable. In support of this, that the 
two mares in question had only seroconverted by Day 28 post transfer, at which point their 
respective antibody titers were 1:16 and 1:64. 
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 Not withstanding the two mares in which it was shown that EAV could be transmitted by 
ET, there were certain limitations to how this study was carried out. In light of the complex and 
expensive nature of the study, as well as state-imposed limitations on the use of a virus 
considered non-endemic in the state in which the study was conducted, individual isolation 
facilities were not available for recipient mares. The inability to achieve strict isolation of each 
mare may have increased the risk of cross-contamination between the paddocks acc mmodating 
donor and recipient mares respectively. The potential for this to occur was recognized by the 
researchers, and every effort was made to ensure that inadvertent transmission of the virus did not 
occur. The donor and recipient mares, while kept in the same isolation area, we  maintained in 
completely separate paddocks, and all equipment was disinfected after use on each mare. 
Nevertheless, in spite of the biosecurity measures that were enforc d, this possibility of 
transmission of EAV to the two mares that became infected other than by embr o transfer must 
be borne in mind when interpreting the results of this study. 
 It is difficult to determine from this study if EAV has an effect on fertility and early 
embryonic development, but the rate of embryos of unsatisfactory quality for transfer was high; 4 
of 16 (25%) in unvaccinated mares and 1 of 8 (12.5%) in vaccinated mares. There was a similarly 
low rate of successful transfer from unvaccinated mares of 3 of 11 at Day 14 (with 1 of 3 
subsequently dying) and vaccinated mares of 2 of 7 (with 1 of 2 subsequently dying); these low 
rates may have been due to trypsin treatment of the embryos or to virus contamination that may 
adversely affect embryonic development. Due to experimental limitations, a group of recipient 
mares receiving non-trypsin washed embryos derived from mares inseminated with EAV-
negative semen was not included in the study. Perhaps the washing and trypsin treatment protocol 
which the embryos were subjected to after collection may have harmed the mbryo and resulted 
in its failure to develop. The equine embryo is considered to lose its ZP approximately 24 h after 
entering the uterus, which often occurs at ~6.5 d after ovulation and capsule formation [43]. 
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These embryos were collected at approximately 7 d after ovulation when many were in the 
expanded blastula stage, with a very thin ZP. Because of the thinness of the ZP, however, the 
process of losing the ZP was difficult to assess. The ZP may have been so thin as to fail to fully 
preclude the effect of trypsin on the trophectodermal layer. In other species su h as cattle, 
exposure of embryos to trypsin during washing did not decrease embryonic survival [47-49]. In 
the cow, the embryo typically does not hatch until 9-11 d post ovulation, and so the continued 
presence of the ZP may protect the underlying blastocyst from the detrimental effects of trypsin. 
In some ways, the equine capsule is more resistant to degradation than the ZP. Whereas exposure 
of the ZP to acidic conditions (pH 2.0), basic conditions (pH 12.0), urea, high temperature (65 ⁰C 
for 60 min or 80 ⁰C for 30 min), mercaptoethanol, and dithiothreitol resulted in the solubilization 
of the ZP, it did not appear to affect the capsule at the concentrations used. However, the capsule 
was completely solubilized using a trypsin solution at pH between 7.5 and 9.0 [50,51]. Despite 
evidence of the adverse effect of trypsin on the capsule and the expectation th t embryos at the 
time of recovery from donor mares would have only a thin ZP remaining, the trypsin wa h 
method has been used consistently as the recommended method to remove infectious agents from 
embryos of other species. Although trypsin treatment of the ZP denuded embryos in this study 
may have detrimentally affected pregnancy rates, it was critical to determine if the trypsin and 
wash protocol as widely used by the IETS would effectively decontaminate the embryos of EAV, 
since this embryonic stage is commonly flushed in clinical practice [53]. In the same way that the 
presence or absence of the ZP may have influenced the effects of trypsin on the embryo, the 
interaction between the virus and the embryo could be different, depending on the presence or 
absence of the ZP. The stage of the embryo at time of collection also may be a critical factor with 
respect to both trypsin treatment and the ability of the wash protocol to remove EAV. 
 Of the five pregnancies diagnosed at 14 d, two were subsequently lost before th  study 
was concluded on Day 60 post transfer. The two mares which lost their pregnanci s did not 
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exhibit any detectable abnormalities on physical examination. Virus was not detected in the 
uterine flush fluid/fetal tissues, and neither mare became seropositive. Early embryonic death has 
not been shown to be a proven feature of EAV infection [54]. Based on the design of this study, 
the factor(s) responsible for the loss of pregnancies before Day 21 could not be determined. All 
three pregnancies that progressed until terminated at 60 d did so without problem, and EAV was 
not detected from any of the fetal tissues collected. This finding was consistent with the results of 
a study that assessed the effects of EAV-positive semen on mare fertility in which pregnancy 
rates were similar between mares bred with virus positive and virus negative semen [54]. In light 
of the low number of pregnancies following embryo transfer with embryos subjected to the IETS 
protocol, the effects of this protocol on the equine embryo, especially the inclusion of the trypsin 
treatment, needs to be further investigated.  
 Vaccination of the embryo donor mare (Group VD) appeared to reduce the likelihood of 
the virus being present in the uterus at the time the embryo was collected, 7 d after breeding, with 
only 2 of 11 uterine flush fluid samples virus positive from Group VD, compared with 9 of 15 
virus positive uterine flush fluid samples from the non-vaccinated mare group. In addition, virus 
was not detected in any of the wash fluid samples from Group VD. These findings would support 
the recommendation to vaccinate mares to be bred with EAV-infective semen. Likewise, it would 
seem prudent to vaccinate embryo recipient mares in clinical practice. The embryo recipient 
mares were not vaccinated in this study so that they could be tested for the presence of EAV 
antibodies following embryo transfer. 
Following breeding with EAV-infective semen, clinical signs displayed by the mares 
were recorded to assess the severity of the infection and to determine if vaccination provided 
protection from the development of clinical signs. Rectal temperatures of each mare were used as 
an objective measure of a clinical response from breeding with infective semen, and the elevated 
body temperatures seen in the NV mares were generally associated with the presence of nasal 
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discharge. With a significant difference of >1.1 ⁰C between the NV and VD groups demonstrated 
in the mean body temperatures on Days 6, 7, and 8, it is apparent that breeding with this strain of 
EAV infective semen caused elevation in body temperature in unvaccinated m r s and that 
vaccination clearly minimized the chance of developing an increased body temperature following 
breeding with EAV infective semen. The clinical signs observed were consistent with the 
elevated temperatures seen in the non-vaccinated donor group in comparisn with the vaccinated 
donor group. The increased incidence of clinical signs consistent with EVA including the 
elevation in body temperature indicates that the challenge dose and strain of EAV used in this 
study were sufficient to elicit a clinical response. Based on the low numbers of p egnancies 
achieved following embryo collection from both the vaccinated and the unvacci ated mares, it 
does not appear that the elevated body temperatures seen in the non-vaccinated group had a 
detrimental effect on the viability of the embryos collected. However, th low number of 
pregnancies achieved in both groups limited the relevance of these findings. 
 The results of this study demonstrated that under the stated experimental conditions, 
EAV can be transmitted via embryo transfer even after the embryos have been washed and 
trypsin treated, in accordance with the IETS protocol. This was supported both by failure of the 
IETS protocol to decontaminate all washed and treated embryos of EAV, together with the fact 
that EAV was successfully transmitted by embryo transfer, albeit in a very limited number of 
cases; more detailed studies are needed to corroborate this finding. However, in view of the 
prohibitive expense of maintaining all the recipient mares in individual isolation facilities, the 
possibility of virus transmission from a source other than an infective embryo cannot be 
completely excluded.  In light of the findings of this study, it is highly recommended that both 
donor and recipient mares be vaccinated against EVA if the former are to be bred with EAV-
infective semen. Additionally, appropriate biosecurity measures need be implemented at time of 
breeding and embryo transfer to minimize the risk of inadvertent lateral spread of EAV infection 
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when using virus positive semen. Additional studies are warranted to further investigate the 
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EMBRYO TRANSFER STUDY APPENDICES 
 
Fig. 1. Mean body temperatures (⁰C) from the non-vaccinated embryo donor (D) group (black line) and 
vaccinated embryo donor (VD) group (grey line) in mares inseminated with equine arteritis virus infective 
semen. 
 




Table 1. Results of virus isolation (VI) and serologic testing (SNT) of donor mares inseminated with equine arteritis virus infective semen. Mares D1-D15 
comprised the non-vaccinated group, whereas Mares VD16-VD26 comprised the initial vaccinated group.  
Mare                SNT     
Buffy Coat 
VI 
    
  
Nasopharyngeal Swab VI 
  
  
Vaginal Swab VI 
    
No. 0 da 7 d 14 d 28 d 0 d 7 d 14 d 28 d 0 d 7 d 14 d 28 d 0 d 7 d 14 d 28 d 
D1 <1:4 <1:4 <1:4 <1:4 -b - - - - - - - - - - - 
D2 <1:4 <1:4  1:16  1:8 - +c + - - - - - - + - - 
D3 <1:4 <1:4 <1:4 <1:4 - - - - - - - - - - - - 
D4 <1:4 <1:4  1:128  1:128 - - - - - - - - - + + - 
D5 <1:4  1:8  1:128  1:32 - + - - - + - - + + + - 
D6 <1:4 <1:4  1:32  1:8 - + - - - + + - - + - - 
D7 <1:4 <1:4  1:32  1:4 - + - - - + - - - + - - 
D8 <1:4 <1:4  1:128  1:32 - + - - - - - - - - + - 
D9 <1:4 <1:4 <1:4  1:32 - - - - - - - - - + - - 
D10 <1:4 <1:4  1:128  1:64 - - - - - + - - - + - - 
D11 <1:4 <1:4  1:64  1:64 - + - - - + - - - - - - 
D12 <1:4  1:8  1:64  1:64 - - - - - - - - - - - - 
D13 <1:4 <1:4  1:8  1:32 - + - - - + + - - - - - 
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D14 <1:4 <1:4  1:32  1:256 - + - - - + - - - - - - 
D15 <1:4 <1:4  1:64  1:16 - + - - - + - - - + - - 
VD16  1:8 ≥1:512 ≥1:512 ≥1:512 - - - - - - - - - - - - 
VD17  1:128 ≥1:512 ≥1:512 ≥1:512 - - - - - - - - - + - - 
VD18  1:256  1:128 ≥1:512 ≥1:512 - - - - - - - - - - - - 
VD19  1:128  1:256 ≥1:512 ≥1:512 - - - - - - - - - + - - 
VD20  1:64 ≥1:512 ≥1:512 ≥1:512 - - - - - - + - - - - - 
VD21  1:32  1:128 ≥1:512 ≥1:512 - - - - - - - - - - - - 
VD22 ≥1:512 ≥1:512 ≥1:512 ≥1:512 - - - - - - - - - - - - 
VD23  1:256 ≥1:512 ≥1:512 ≥1:512 - - - - - - - - - - - - 
VD24  1:32  1:256 ≥1:512 ≥1:512 - - - - - + - - - + - - 
VD25  1:256 ≥1:512 ≥1:512 ≥1:512 - - - - - - - - - + - - 
VD26 ≥1:512  1:256 ≥1:512 ≥1:512 - - - - - - - - - - - - 
 (a) d = days after insemination 
(b) - = negative on VI  
(c) + = positive on VI and confirmed positive by PCR
 
 
Table 2. Results of serologic testing of embryo recipient mares following embryo transfer. 
Recipient 
mare No. 








R1 <1:4 <1:4  D7 Prega +b 
R2 <1:4 1:16 D12 NPc + 
R3 <1:4 <1:4  D1 NP -d 
R4 <1:4  <1:4  VD19 NP + 
R5 NSe <1:4 D5 NP - 
R6 <1:4 <1:4 D11 NP + 
R7 NS <1:4 D5 NP - 
R8 <1:4 <1:4  D1 NP - 
R9 <1:4 <1:4  D9 NP - 
R10 <1:4 <1:4  D10 Preg - 
R11 <1:4 <1:4  D8 Preg + 
R12 <1:4 <1:4  VD23 Preg - 
R13 <1:4 1:64 D15 NP + 
R14 <1:4 <1:4  VD18 NP - 
R15 <1:4 <1:4  VD16 NP - 
R16 <1:4 <1:4  VD17 Preg - 
R17 <1:4 <1:4 VD25 NP - 
R18 <1:4 <1:4 VD20 NP - 
 
(a) Preg = pregnant 
(b) + = positive on VI and confirmed positive by PCR  
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(c) NP = not pregnant 
(d) - = negative on VI 
 
(e) NS = not sampled 
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Table 3. Results of virus isolation and PCR testing of uterine flush fluid collected at time of 
embryo collection, subsequent washes of recovered embryos, and the embryo if not transferred; 
number of embryos recovered and disposition.  
Donor No. Flush Wash 1 Wash 3 Wash 5 Wash 6 Wash 8 
Wash 
10 
Number of embryos 
recovered and 
disposition 
D1a -b - - - - - - 
3–Tr(R3)c, Tr(R8),Tst(-
)d 
D2 +e ENRf ENR ENR ENR ENR ENR 0 
D3 + - - + + - + 1 – Tst(-) 
D4 + + + + + - + 1 – Tst(+) 
D5 - + - - - - - 2 – Tr(R5), Tr(R7) 
D6 - ENR ENR ENR ENR ENR ENR 0 
D7 + - - - - - - 1 – Tr(R1) 
D8 + + - - - - - 1 – Tr(R11) 
D9 - - - - - - - 1 – Tr(R9) 
D10 - - - - - - - 1 – Tr(R10) 
D11 + + - - - - - 3-Tr(R6), Tr(R6), Tst(-) 
D12 + - - - - - - 1 – Tr(R2) 
D13 - ENR ENR ENR ENR ENR ENR 0 
D14 + ENR ENR ENR ENR ENR ENR 0 
D15 + - - - - - - 1 – Tr(R13) 
VD16g - - - - - - - 1-Tr(R15) 
VD17 - - - - - - - 1-Tr(R16) 
VD18 - - - - - - - 1-Tr(R14) 
VD19 + - - - - - - 1-Tr(R4) 
VD20 - - - - - - - 2-Tr(R18), Tst(-) 
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VD21 - ENR ENR ENR ENR ENR ENR 0 
VD22 - ENR ENR ENR ENR ENR ENR 0 
VD23 - - - - - - - 1-Tr(R12) 
VD24 + ENR ENR ENR ENR ENR ENR 0 
VD25 - - - - - - - 1-Tr(R17) 
VD26 - ENR ENR ENR ENR ENR ENR 0 
 (a) Mares D1-D15 comprised the non-vaccinated donor group 
(b) - = negative by VI 
 (c) Tr(x) = embryo transferred into mare x 
(d) Tst(+ or -) = embryo not transferred and directly tested by VI and PCR 
(e) + = positive by VI and confirmed by PCR 
(f) ENR = embryo not recovered 
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